0001000228-23-000011 | 10-K | XBRL Viewer

Print Document View Excel Document

Cover Page - USD ($)	12 Months Ended
Cover Page - USD ($)	Dec. 31, 2022	Feb. 07, 2023	Jun. 25, 2022
Cover Page
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN INC
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Public Float			$ 10,463,590,000
Entity Common Stock, Shares Outstanding		131,283,515
Entity Voluntary Filers	No
Documents Incorporated by Reference	Portions of the Registrant’s definitive proxy statement to be filed pursuant to Regulation 14A not later than 120 days after the end of the fiscal year (December 31, 2022) are incorporated by reference in Part III hereof.
ICFR Auditor Attestation Flag	true
AuditorName	BDO USA, LLP
Auditor Firm Id	243
Auditor Location	New York, NY

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Current assets:
Cash and cash equivalents	$ 117	$ 118
Accounts receivable, net of reserves of $65 and $67	1,442	1,452
Inventories, net	1,963	1,861
Prepaid expenses and other	466	413
Total current assets	3,988	3,844
Property and equipment, net	383	366
Operating lease right-of-use assets	284	325
Goodwill	2,893	2,854
Other intangibles, net	587	668
Investments and other	472	424
Total assets	8,607	8,481
Current liabilities:
Accounts payable	1,004	1,054
Bank credit lines	103	51
Current maturities of long-term debt	6	11
Operating lease liabilities	73	76
Accrued expenses:
Payroll and related	314	385
Taxes	132	137
Other	592	593
Total current liabilities	2,224	2,307
Long-term debt	1,040	811
Deferred income taxes	36	42
Operating lease liabilities	275	268
Other liabilities	361	377
Total liabilities	3,936	3,805
Redeemable noncontrolling interests	576	613
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $0.01 par value, 480,000,000 shares authorized, 131,792,817 outstanding on December 31, 2022 and 137,145,558 outstanding on December 25, 2021	1	1
Additional paid-in capital	0	0
Retained earnings	3,678	3,595
Accumulated other comprehensive loss	(233)	(171)
Total Henry Schein, Inc. stockholders' equity	3,446	3,425
Noncontrolling interests	649	638
Total stockholders' equity	4,095	4,063
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 8,607	$ 8,481

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Current assets:
Accounts receivable, reserves (in dollars)	$ 65	$ 67
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	131,792,817	137,145,558

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	12 Months Ended
CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Income Statement [Abstract]
Net sales	$ 12,647	$ 12,401	$ 10,119
Cost of sales	8,816	8,727	7,303
Gross profit	3,831	3,674	2,816
Operating expenses:
Selling, general and administrative	2,771	2,634	2,086
Depreciation and amortization	182	180	163
Restructuring and integration costs	131	8	32
Operating income	747	852	535
Other income (expense):
Interest income	17	7	10
Interest expense	(44)	(28)	(41)
Other, net	1	0	(4)
Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests	721	831	500
Income taxes	(170)	(198)	(95)
Equity in earnings of affiliates	15	20	12
Gain on sale of equity investment	0	7	2
Net income from continuing operations	566	660	419
Income from discontinued operations, net of tax	0	0	1
Net Income	566	660	420
Less: Net income attributable to noncontrolling interests	(28)	(29)	(16)
Net income attributable to Henry Schein, Inc.	538	631	404
Amounts attributable to Henry Schein Inc.:
Continuing Operations	538	631	403
Discontinued operations	0	0	1
Net income attributable to Henry Schein, Inc.	$ 538	$ 631	$ 404
Earnings per share from continuing operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 3.95	$ 4.51	$ 2.83
Diluted (in dollars per share)	3.91	4.45	2.81
Earnings per share from discontinued operations attributable to Henry Schein, Inc.:
Basic (in dollars per share)	0	0	0.01
Diluted (in dollars per share)	0	0	0.01
Earnings per share attributable to Henry Schein, Inc.
Basic (in dollars per share)	3.95	4.51	2.83
Diluted (in dollars per share)	$ 3.91	$ 4.45	$ 2.82
Weighted-average common shares outstanding:
Basic (in shares)	136,064,221	140,090,889	142,504,193
Diluted (in shares)	137,755,670	141,772,781	143,403,682

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Statement of Comprehensive Income [Abstract]
Net Income	$ 566	$ 660	$ 420
Other comprehensive income, net of tax:
Foreign currency translation gain (loss)	(88)	(84)	63
Unrealized gain (loss) from foreign currency hedging activities	7	9	(7)
Pension adjustment gain	12	6	0
Other comprehensive income (loss), net of tax	(69)	(69)	56
Comprehensive income	497	591	476
Comprehensive income attributable to noncontrolling interests:
Net income	(28)	(29)	(16)
Foreign currency translation loss	7	6	3
Comprehensive income attributable to noncontrolling interests	(21)	(23)	(13)
Comprehensive income attributable to Henry Schein, Inc.	$ 476	$ 568	$ 463

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Common Stock [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Retained Earnings [Member]	Retained Earnings [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Other Comprehensive Income (Loss) [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]	Noncontrolling Interests [Member]	Noncontrolling Interests [Member] Cumulative Effect, Period of Adoption, Adjustment [Member]
Beginning Balance at Dec. 28, 2019	$ 3,630		$ 1		$ 48		$ 3,116		$ (167)		$ 632
Beginning Balance (in shares) at Dec. 28, 2019			143,353,459
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	406		$ 0		0		404		0		2
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	67		0		0		0		66		1
Unrealized gain (loss) from foreign currency hedging activities, net of tax expense (benefit)	(7)		0		0		0		(7)		0
Pension adjustment gain (loss), net of tax impact	0
Dividends paid	(1)		0		0		0		0		(1)
Purchase of noncontrolling interests	(3)		0		(2)		0		0		(1)
Change in fair value of redeemable securities	(33)		0		(33)		0		0		0
Noncontrolling interests and adjustments related to business acquisitions	3		0		0		0		0		3
Repurchase and retirement of common stock - Value	(74)		$ 0		(11)		(63)		0		0
Repurchase and retirement of common stock - Shares			(1,200,000)
Stock-based compensation expense - Value	9		$ 0		9		0		0		0
Stock-based compensation expense - Shares			545,864
Shares withheld for payroll taxes - Value	(15)		$ 0		(15)		0		0		0
Shares withheld for payroll taxes - Shares			(236,752)
Separation of Animal Health business	2		$ 0		2		0		0		0
Transfer of charges in excess of capital	0		0		2		(2)		0		0
Ending Balance at Dec. 26, 2020	3,984		$ 1		0		3,455		(108)		636
Ending Balance (in shares) at Dec. 26, 2020			142,462,571
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	637		$ 0		0		631		0		6
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)	(78)		0		0		0		(78)		0
Unrealized gain (loss) from foreign currency hedging activities, net of tax expense (benefit)	9		0		0		0		9		0
Pension adjustment gain (loss), net of tax impact	6		0		0		0		6		0
Dividends paid	(11)		0		0		0		0		(11)
Change in fair value of redeemable securities	(160)		0		(160)		0		0		0
Noncontrolling interests and adjustments related to business acquisitions	7		0		0		0		0		7
Repurchase and retirement of common stock - Value	(401)		$ 0		(53)		(348)		0		0
Repurchase and retirement of common stock - Shares			(5,505,704)
Stock-based compensation expense - Value	78		$ 0		78		0		0		0
Stock-based compensation expense - Shares			303,643
Shares withheld for payroll taxes - Value	(8)		$ 0		(8)		0		0		0
Shares withheld for payroll taxes - Shares			(114,952)
Transfer of charges in excess of capital	0		$ 0		(143)		143		0		0
Ending Balance at Dec. 25, 2021	$ 4,063		$ 1		0		3,595		(171)		638
Ending Balance (in shares) at Dec. 25, 2021	137,145,558		137,145,558
Net income (excluding amounts attributable to Redeemable noncontrolling interests)		$ 545		$ 0		$ 0		$ 538		$ 0		$ 7
Foreign currency translation gain (loss) (excluding amounts attributable to Redeemable noncontrolling interests)		(82)		0		0		0		(81)		(1)
Unrealized gain (loss) from foreign currency hedging activities, net of tax expense (benefit)	$ 7	7		0		0		0		7		0
Pension adjustment gain (loss), net of tax impact	12	12		0		0		0		12		0
Dividends paid		(1)		0		0		0		0		(1)
Purchase of noncontrolling interests	(7)		$ 0		0		0		0		(7)
Change in fair value of redeemable securities		4		0		4		0		0		0
Noncontrolling interests and adjustments related to business acquisitions	13		0		0		0		0		13
Repurchase and retirement of common stock - Value		(485)		$ 0		(65)		(420)		0		0
Repurchase and retirement of common stock - Shares				(6,111,676)
Stock issued upon exercise of stock options, Value	2		$ 0		2		0		0		0
Stock issued upon exercise of stock options, shares			35,792
Stock-based compensation expense - Value		54		$ 0		54		0		0		0
Stock-based compensation expense - Shares				1,102,108
Shares withheld for payroll taxes - Value		(32)		$ 0		(32)		0		0		0
Shares withheld for payroll taxes - Shares				(376,034)
Settlement of stock-based compensation awards	2		$ 0		$ 2		$ 0		$ 0		$ 0
Settlement of stock-based compensation awards, shares			(2,931)
Transfer of charges in excess of capital		0		$ 0		35		(35)		0		0
Ending Balance at Dec. 31, 2022	$ 4,095	$ 4,095		$ 1		$ 0		$ 3,678		$ (233)		$ 649
Ending Balance (in shares) at Dec. 31, 2022	131,792,817			131,792,817

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Statement of Stockholders' Equity [Abstract]
Unrealized gain (loss) from foreign currency hedging activities, tax expense (benefit)	$ (3)	$ (3)	$ 3
Unrealized investment gain (loss), tax benefit (tax)	0	0	0
Pension adjustment gain (loss), tax benefit (tax)	4	2	0
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests	21	23
Foreign currency translation (gain) loss	$ 6	$ 6	4
Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests			14
Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income attributable to redeemable noncontrolling interests			$ 0

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Cash flows from operating activities:
Net Income	$ 566	$ 660	$ 420
Income from discontinued operations	0	0	1
Income from continuing operations	566	660	419
Adjustments to reconcile net income to net cash provided by operating activities: operating activities:
Depreciation and amortization	212	210	186
Impairment charge on intangible assets	34	1	20
Non-cash restructuring charges	93	0	0
Gain on sale of equity investment	0	(10)	(2)
Stock-based compensation expense	54	78	9
Provision for (benefits from) losses on trade and other accounts receivable	5	(8)	35
Benefit from deferred income taxes	(73)	(11)	(53)
Equity in earnings of affiliates	(15)	(20)	(12)
Distributions from equity affiliates	15	18	16
Changes in unrecognized tax benefits	12	(2)	(25)
Other	(20)	(10)	32
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(7)	4	(189)
Inventories	(126)	(295)	(32)
Other current assets	(52)	9	(6)
Accounts payable and accrued expenses	(96)	86	196
Net cash provided by operating activities from continuing operations	602	710	594
Net cash provided by operating activities from discontinued operations	0	0	5
Net cash provided by operating activities	602	710	599
Cash flows from investing activities:
Purchases of fixed assets	(96)	(79)	(49)
Payments related to equity investments and business acquisitions, net of cash acquired	(158)	(571)	(60)
Proceeds from sale of equity investment	0	10	14
Proceeds from (repayments to) loan to affiliate	11	(4)	(1)
Other	(33)	(33)	(19)
Net cash used in investing activities	(276)	(677)	(115)
Cash flows from financing activities:
Net change in bank borrowings	48	(18)	45
Proceeds from issuance of long-term debt	270	305	501
Principal payments for long-term debt	(59)	(122)	(611)
Debt issuance costs	0	(3)	(4)
Proceeds from issuance of stock upon exercise of stock options	2	0	0
Payments for repurchases of common stock	(485)	(401)	(74)
Payments for taxes related to shares withheld for employee taxes	(32)	(8)	(14)
Distributions to noncontrolling stockholders	(21)	(26)	(8)
Acquisitions of noncontrolling interests in subsidiaries	(38)	(60)	(19)
Proceeds from Henry Schein Animal Health Business	0	0	2
Net cash used in financing activities from continuing operations	(315)	(333)	(182)
Net cash provided by (used in) financing activities from discontinued operations	0	0	(5)
Net cash used in financing activities	(315)	(333)	(187)
Effect of exchange rate changes on cash and cash equivalents from continuing operations	(12)	(3)	18
Net change in cash and cash equivalents from continuing operations	(1)	(303)	315
Cash and cash equivalents, beginning of period	118	421	106
Cash and cash equivalents, end of period	$ 117	$ 118	$ 421

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Basis of Presentation and Significant Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Note 1 –Basis of Presentation and Significant Accounting Policies Nature of Operations We distribute health care products and services primarily to office-based dental and medical practitioners, across dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics and alternate care clinics. We also provide software, technology and other value- added services to health care practitioners. Our dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices and integrated delivery networks, among other providers across a wide range of specialties. We have operations or affiliates in the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, Mexico, the Netherlands, New Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom. Basis of Presentation Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates in which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our consolidated financial condition, results of operations or cash flows. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At December 31, 2022 and December 25, 2021, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 327 million and $ 138 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 255 million and $ 105 million, respectively. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. Demand for these non-PPE products increased in the second half of 2020 and continued throughout the years ended December 25, 2021 and December 31, 2022, resulting in growth over the prior years. Demand for PPE products declined during the year ended December 31, 2022. Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time. Fiscal Year We report our results of operations and cash flows on a 52 - 53 week basis ending on the last Saturday of December. The year ended December 31, 2022 consisted of 53 weeks, and the years ended, December 25, 2021 and December 26, 2020 consisted of 52 weeks. Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that we expect to receive for those goods or services. To recognize revenue, we do the following: • identify the contract(s) with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the performance obligations in the contract; and • recognize revenue when, or as, the entity satisfies a performance obligation. We generate revenue from the sale of dental and medical consumable products, equipment (Health care distribution revenues), software products and services and other sources (Technology and value-added services revenues). Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included in the transaction price at contract inception by estimating the most likely amount based upon historical data and estimates and are provided for in the period in which the related sales are recognized. Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the customer. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating control has transferred to the customer because we have no post-shipment obligations and this is when legal title and risks and rewards of ownership transfer to the customer and the point at which we have an enforceable right to payment. Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Most equipment requires minimal installation, which is typically completed at the time of delivery. Our product generally carries standard warranty terms provided by the manufacturer, however, in instances where we provide warranty labor services, the warranty costs are accrued in accordance with Accounting Standards Codification (“ASC”) 460 “Guarantees”. At December 31, 2022 and December 25, 2021, we had accrued approximately $ 8 million and $ 8 million, respectively, for warranty costs. Revenue derived from the sale of software products is recognized when products are delivered to customers or made available electronically. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is generally recognized over time using time elapsed as the input method that best depicts the transfer of control to the customer. Revenue derived from software sold on Software-as-a - Service basis is recognized ratably over the subscription period as control is transferred to the customer. Revenue derived from other sources, including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided. We apply the practical expedient to treat shipping and handling activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in the contract. Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations, which are accounted for separately. When we sell software products together with related services (i.e., training and technical support), we allocate revenue to software using the residual method, using an estimate of the standalone selling price to estimate the fair value of the undelivered elements. Bundled arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an observable selling price is not available (i.e., we do not sell the goods or services separately), we use one of the following techniques to estimate the standalone selling price: adjusted market approach; cost-plus approach; or the residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions. Sales Returns Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund liability within current liabilities. We estimate the amount of revenue expected to be reversed to calculate the sales return liability based on historical data for specific products, adjusted as necessary for new products. The allowance for returns is presented gross as a refund liability and we record an inventory asset (and a corresponding adjustment to cost of sales) for any products that we expect to be returned. Cost of Sales The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs. Total distribution network costs were $ 103 million, $ 89 million and $ 72 million for the years ended December 31, 2022, December 25, 2021 and December 26, 2020. Supplier Rebates Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume. Direct Shipping and Handling Costs Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct handling costs were $ 96 million, $ 97 million and $ 79 million for the years ended December 31, 2022, December 25, 2021 and December 26, 2020. Advertising and Promotional Costs We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $ 47 million, $ 48 million and $ 32 million for the years ended December 31, 2022, December 25, 2021 and December 26, 2020. Stock Compensation Costs We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period for time-based restricted stock units and on a graded vesting basis for the option awards. For performance-based awards, at each reporting date, we reassess whether achievement of the performance condition is probable and accrue compensation expense when achievement of the performance condition is probable. Our stock-based compensation expense is reflected in selling, general and administrative expenses. Employment Benefit Plans and other Postretirement Benefit Plans Certain of our employees in our international markets participate in various noncontributory defined benefit plans. We recognize the funded status, measured as the difference between the fair value of plan assets and the benefit obligation, of each applicable plan, within accumulated other comprehensive income in the consolidated balance sheets, whereby each unfunded plan is recognized as a liability and each funded plan is recognized as either an asset or liability based on its funded status. We measure our plan assets and liabilities at the end of our fiscal year. Net periodic pension costs and valuations are dependent on assumptions used by third-party actuaries in calculating those amounts. These assumptions include discount rates, expected return on plan assets, rate of future compensation levels, retirement rates, mortality rates, and other factors. We record the service cost component of net pension cost in selling, general and administrative expenses within our consolidated statements of income. Cash and Cash Equivalents We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $ 54 million and $ 2 million, primarily related to payments for inventory, were classified as accounts payable as of December 31, 2022 and December 25, 2021. Contract Balances Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities. Accounts Receivable and Allowance for Credit Losses Accounts receivable are generally recognized when health care distribution and technology and value-added services revenues are recognized. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that we do not expect to collect. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. We record allowances for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided at differing rates, based upon the age of the receivable, the collection history associated with the geographic region that the receivable was recorded in, current economic trends and reasonable supportable forecasts. We write-off a receivable and charge it against its recorded allowance when we deem them uncollectible. Our allowance for doubtful accounts was $ 65 million, $ 67 million and $ 88 million as of December 31, 2022, December 25, 2021 and December 26, 2020, respectively. Additions to the allowance for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 were $ 8 million, $ 0 million and $ 36 million. Deductions to the allowance for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 were $ 10 million, $ 21 million and $ 8 million. Contract Assets Contract assets include amounts related to any conditional right to consideration for work completed but not billed as of the reporting date, and generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current contract assets are included in Prepaid expenses and other and the non-current contract assets are included in investments and other within our consolidated balance sheets. Current and non-current contract asset balances as of December 31, 2022 and December 25, 2021 were not material. Contract Liabilities Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in accrued expenses: Other and the non-current contract liabilities are included in other liabilities within our consolidated balance sheets. At December 25, 2021, the current portion of contract liabilities of $ 89 million was reported in accrued expenses: Other, and $ 10 million related to non-current contract liabilities was reported in other liabilities. During the year ended December 31, 2022, we recognized substantially all of the current contract liability amounts that were previously deferred at December 25, 2021. At December 31, 2022, the current and non-current portion of contract liabilities were $ 86 million and $ 8 million, respectively. Inventories and Reserves Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Capitalized Software Development Costs Capitalized internal-use software costs consist of costs to purchase and develop software. For software to be used solely to meet internal needs and cloud-based applications used to deliver our services, we capitalize costs incurred during the application development stage and include such costs within property and equipment, net within our consolidated balance sheets. For software to be sold, leased, or marketed to external users, we capitalize software development costs when technological feasibility is reached and include such costs in Investments and other within our consolidated balance sheets. Leases We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in operating lease right-of-use (“ROU”) assets, operating lease liabilities, and non-current operating lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, current maturities of long-term debt, and long-term debt in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the estimated rate of interest for fully collateralized and fully amortizing borrowings over a similar term of the lease payments at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Expenses associated with operating leases and finance leases are included in “selling, general and administrative” and “interest expense”, respectively within our consolidated statement of income. Short-term leases with a term of 12 months or less are not capitalized. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, such short-term lease expense was $ 7 million, $ 4 million, and $ 2 million, respectively. We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles, which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price. Goodwill Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired, including the amount assigned to identifiable intangible assets. Goodwill is subject to impairment analysis annually or more frequently if needed. Such impairment analyses for goodwill requires a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: global dental; global medical; and technology and value-added services. Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis. For the years ended December 31, 2022 and December 25, 2021, we tested goodwill for impairment, on the first day of the fourth quarter, using a quantitative analysis comparing the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. Conversely, impairment loss would be equivalent to the excess of a reporting unit’s carrying value over its fair value limited to the total amount of goodwill allocated to that reporting unit. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities that are considered shared services to the reporting units, and ultimately the determination of the fair value of each reporting unit. The fair value of each reporting unit is calculated by applying the discounted cash flow methodology and confirming with a market approach. There are inherent uncertainties related to fair value models, the inputs and our judgments in applying them to this analysis. The most significant inputs include estimation of future cash flows based on budget expectations, and determination of comparable companies to develop a weighted average cost of capital for each reporting unit. For the year ended December 31, 2022, we recorded a $ 20 million impairment of goodwill relating to the disposal of an unprofitable business whose estimated fair value was lower than its carrying value. The disposal of this business is part of our restructuring initiative as more fully discussed in For the year ended December 25, 2021, the results of our goodwill impairment analysis did no t result in any impairments. Intangible Assets Intangible assets, other than goodwill, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows to be derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and product development. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded total impairment charges on intangible assets of $ 34 million, $ 1 million and $ 20 million, respectively, as more fully discussed in Income Taxes We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries Redeemable Noncontrolling Interests Some minority stockholders in certain of our consolidated subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. Adjustments to the carrying amount of noncontrolling interests to reflect a fair value redemption feature do not impact the calculation of earnings per share. Our net income is reduced by the portion of the subsidiaries’ net income that is attributable to redeemable noncontrolling interests. Noncontrolling Interests Non-controlling interest represents the ownership interests of certain minority owners of our consolidated subsidiaries. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests. Comprehensive Income Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) from foreign currency hedging activities and pension adjustment gain. Risk Management and Derivative Financial Instruments We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers and foreign currency swaps related to foreign currency denominated debt are designated as cash flow hedges. For derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivative is recorded as a component of Accumulated other comprehensive income in stockholders’ equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item. Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net investment hedges. For derivatives that are designated and qualify as net investment hedges, the changes in the fair value of the derivative is recorded in the foreign currency translation gain (loss) component of Accumulated other comprehensive income in stockholders’ equity until the net investment is sold or substantially liquidated. Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes. For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in other, net, within our consolidated statements of income. Total return swaps are entered into for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. This swap is expected to be renewed on an annual basis and is recorded in selling, general, and administrative expenses within our consolidated statements of income. Foreign Currency Translation and Transactions The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in earnings. Accounting Pronouncements Adopted On December 26, 2021 we adopted Accounting Standards Update (“ASU”) No. 2021 – 08, “Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (Subtopic 805). ASU 2021 – 08 requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASU No. 2014 - 09, “Revenue from Contracts with Customers” (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. Our adoption of ASU 2021 - 08 did not have a material impact on our consolidated financial statements. On December 27, 2020 we adopted ASU No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements. Recently Issued Accounting Standards In September 2022, the FASB issued ASU No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405- 50): Disclosure of Supplier Finance Program Obligations” which will increase transparency of supplier finance programs by requiring entities that use such programs in connection with the purchase of goods and services to disclose certain qualitative and quantitative information about such programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for amended rollforward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope (“ASU 2021-01”). ASU 2021-01 provides temporary optional expedients and exceptions to certain guidance in U.S. GAAP to ease the financial reporting burdens related to the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate. The guidance became effective upon issuance, on January 7, 2021, and can be applied through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” which extends the period of application of temporary optional expedients from December 21, 2022 to December 31, 2024. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements.

Net Sales from Contracts with Customers	12 Months Ended
Net Sales from Contracts with Customers	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Net Sales from Contracts with Customers	Note 2 – Net Sales from Contracts with Customers Net sales is recognized in accordance with policies disclosed in Disaggregation of Net sales The following table disaggregates our Net sales by reportable segment and geographic area: Year Ended December 31, 2022 North America International Global Net Sales: Health care distribution Dental $ 4,628 $ 2,845 $ 7,473 Medical 4,375 76 4,451 Total health care distribution 9,003 2,921 11,924 Technology and value-added services 633 90 723 Net sales $ 9,636 $ 3,011 $ 12,647 Year Ended December 25, 2021 North America International Global Net Sales: Health care distribution Dental $ 4,506 $ 3,038 $ 7,544 Medical 4,107 103 4,210 Total health care distribution 8,613 3,141 11,754 Technology and value-added services 560 87 647 Net sales $ 9,173 $ 3,228 $ 12,401 Year Ended December 26, 2020 North America International Global Net Sales: Health care distribution Dental $ 3,472 $ 2,441 $ 5,913 Medical 3,515 102 3,617 Total health care distribution 6,987 2,543 9,530 Technology and value-added services 447 67 514 Total excluding Corporate TSA net sales (1) 7,434 2,610 10,044 Corporate TSA net sales (1) - 75 75 Net sales $ 7,434 $ 2,685 $ 10,119 (1) Corporate TSA net sales represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Segment and Geographic Data	12 Months Ended
Segment and Geographic Data	Dec. 31, 2022
Segment and Geographic Data [Abstract]
Segment and Geographic Data	Note 3 – Segment and Geographic Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices and integrated delivery networks, among other providers across a wide range of specialties. Our global dental and medical groups serve practitioners in 32 countries worldwide. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, dental specialty products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE and vitamins. Our global technology and value-added services reportable segment provides software, technology and other value- added services to health care practitioners. Our technology offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The following tables present information about our reportable and operating segments: Years Ended December 31, December 25, December 26, 2022 2021 2020 Net Sales: Health care distribution (1) Dental $ 7,473 $ 7,544 $ 5,913 Medical 4,451 4,210 3,617 Total health care distribution 11,924 11,754 9,530 Technology and value-added services (2) 723 647 514 Total excluding Corporate TSA net sales 12,647 12,401 10,044 Corporate TSA net sales (3) - - 75 Total $ 12,647 $ 12,401 $ 10,119 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. (3) Corporate TSA net sales represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. Years ended December 31, December 25, December 26, 2022 2021 2020 Operating Income: Health care distribution $ 619 $ 727 $ 436 Technology and value-added services 128 125 99 Total $ 747 $ 852 $ 535 Income from continuing operations before taxes and equity in earnings of affiliates: Health care distribution $ 592 $ 706 $ 400 Technology and value-added services 129 125 100 Total $ 721 $ 831 $ 500 Depreciation and Amortization: Health care distribution $ 160 $ 157 $ 143 Technology and value-added services 52 53 43 Total $ 212 $ 210 $ 186 Interest Income: Health care distribution $ 16 $ 7 $ 10 Technology and value-added services 1 - - Total $ 17 $ 7 $ 10 Interest Expense: Health care distribution $ 44 $ 28 $ 41 Total $ 44 $ 28 $ 41 Income Tax Expense: Health care distribution $ 141 $ 168 $ 71 Technology and value-added services 29 30 24 Total $ 170 $ 198 $ 95 Purchases of Fixed Assets: Health care distribution $ 86 $ 74 $ 44 Technology and value-added services 10 5 5 Total $ 96 $ 79 $ 49 As of December 31, December 25, December 26, 2022 2021 2020 Total Assets: Health care distribution $ 7,287 $ 7,157 $ 6,503 Technology and value-added services 1,320 1,324 1,270 Total $ 8,607 $ 8,481 $ 7,773 The following table presents information about our operations by geographic area as of and for the three years ended December 31, 2022. Net sales by geographic area are based on the respective locations of our subsidiaries. No country, except for the United States, generated net sales greater than 10 % of consolidated net sales. There were no material amounts of sales or transfers among geographic areas and there were no material amounts of export sales. 2022 2021 2020 Net Sales Long-Lived Assets Net Sales Long-Lived Assets Net Sales Long-Lived Assets United States $ 9,190 $ 2,891 $ 8,722 $ 2,981 $ 7,090 $ 2,363 Other 3,457 1,256 3,679 1,232 3,029 1,252 Consolidated total $ 12,647 $ 4,147 $ 12,401 $ 4,213 $ 10,119 $ 3,615

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Business Acquisitions and Divestitures	12 Months Ended
Business Acquisitions and Divestitures	Dec. 31, 2022
Business Acquisitions and Divestitures [Abstract]
Business Acquisitions and Divestitures	Note 4 – Business Acquisitions and Divestiture Acquisitions We account for business acquisitions and combinations under the acquisition method of accounting, where the net assets of acquired businesses are recorded at their fair value at the acquisition date and our consolidated financial statements include their results of operations from that date. Any excess of acquisition consideration over the fair value of identifiable net assets acquired is recorded as goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized, such as future customers and technology, as well as the assembled workforce. Excluding goodwill, the major classes of assets and liabilities to which we generally allocate acquisition consideration include identifiable intangible assets (i.e., customer relationships and lists, trademarks and trade names, product development, and non-compete agreements), inventory and accounts receivable. The estimated fair value of identifiable intangible assets is based on critical judgments and assumptions derived from analysis of market conditions, including discount rates, projected revenue growth rates (which are based on historical trends and assessment of financial projections), estimated customer attrition and projected cash flows. These assumptions are forward-looking and could be affected by future economic and market conditions. Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration, or we may be entitled to recoup a portion of purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition, using the income approach, including a probability-weighted discounted cash flow method or an option pricing method, where applicable. Any adjustments to these accrual amounts are recorded in selling, general and administrative expenses within our consolidated statements of income. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, within 12 months following the date of acquisition, or the measurement period, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our consolidated statements of operations. 2022 Acquisitions We completed several acquisitions during the year ended December 31, 2022, which were immaterial to our consolidated financial statements. Our acquired ownership interest ranged between 55 % to 100 %. Acquisitions within our health care distribution segment included companies that specialize in the distribution of dental products. Within our technology and value-added services segment, we acquired a company that educates and connects dental office managers, practice administrators and dental business leaders across North America. The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for acquisitions during the year ended December 31, 2022. Approximately half of the acquired goodwill is deductible for tax purposes. 2022 Acquisition consideration: Cash $ 158 Deferred consideration 2 Fair value of previously held equity method investment 16 Redeemable noncontrolling interests 17 Total consideration $ 193 Identifiable assets acquired and liabilities assumed: Current assets $ 41 Intangible assets 96 Other noncurrent assets 13 Current liabilities (29) Deferred income taxes (6) Other noncurrent liabilities (8) Total identifiable net assets 107 Goodwill 86 Total net assets acquired $ 193 The following table summarizes the identifiable intangible assets acquired during the year ended December 31, 2022 and their estimated useful lives as of the date of the acquisition: Estimated Useful Lives 2022 (in years) Customer relationships and lists 81 8 - 12 Trademark / Tradename 9 5 Non-compete agreements 3 2 - 5 Other 3 10 $ 96 The accounting for certain of our acquisitions during the year ended December 31, 2022 had not been completed in several areas, including but not limited to pending assessments of accounts receivable, inventory, intangible assets, right-of-use lease assets, accrued liabilities and income and non-income based taxes. The pro forma financial information has not been presented because the impact of the acquisitions during the year ended December 31, 2022 to our consolidated financial statements was immaterial. 2021 Acquisitions We completed several acquisitions during the year ended December 25, 2021, which were immaterial to our financial statements. Our acquired ownership interests ranged from between approximately 51 % to 100 %. Acquisitions within our health care distribution segment included companies that specialize in the distribution and manufacturing of dental and medical products, a provider of home medical supplies, and a provider of product kitting and sterile packaging. Within our technology and value-added services segment, we acquired companies that focus on dental marketing and website solutions, practice transition services, revenue cycle management, and business analytics and intelligence software. Approximately half of the acquired goodwill is deductible for tax purposes. The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for acquisitions during the year ended December 25, 2021. 2021 Acquisition consideration: Cash $ 579 Deferred consideration 11 Estimated fair value of contingent consideration receivable (5) Fair value of previously held equity method investment 8 Redeemable noncontrolling interests 181 Total consideration $ 774 Identifiable assets acquired and liabilities assumed: Current assets $ 195 Intangible assets 317 Other noncurrent assets 51 Current liabilities (93) Deferred income taxes (26) Other noncurrent liabilities (46) Total identifiable net assets 398 Goodwill 376 Total net assets acquired $ 774 The following table summarizes the identifiable intangible assets acquired during the year ended December 25, 2021 and their estimated useful lives as of the date of the acquisition: Estimated Useful Lives 2021 (in years) Customer relationships and lists $ 220 5 - 12 Trademark / Tradename 58 5 - 12 Product development 19 5 - 10 Non-compete agreements 5 3 - 5 Other 15 18 $ 317 2020 Acquisitions We completed several acquisitions during the year ended December 26, 2020, which were immaterial to our financial statements. Our acquired ownership interests ranged from between approximately 51 % to 100 %. Acquisitions within our health care distribution segment included companies that manufacture endodontic files and companies that distribute dental supplies. Within our technology and value-added services segment, we acquired companies that focus on practice management software and provide software as a solution for dental practices. Approximately half of the acquired goodwill is deductible for tax purposes. The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for acquisitions during the year ended December 26, 2020: 2020 Acquisition consideration: Cash $ 52 Deferred consideration 6 Fair value of previously held equity method investment 9 Redeemable noncontrolling interests 26 Total consideration $ 93 Identifiable assets acquired and liabilities assumed: Current assets $ 36 Intangible assets 38 Other noncurrent assets 22 Current liabilities (21) Deferred income taxes (4) Other noncurrent liabilities (1) Total identifiable net assets 70 Goodwill 23 Total net assets acquired $ 93 The following table summarizes the identifiable intangible assets acquired during the year ended December 26, 2020 and their estimated useful lives as of the date of the acquisition: Estimated Useful Lives 2020 (in years) Customer relationships and lists $ 23 10 - 12 Product development 9 7 - 10 Trademark / Tradename 4 5 Non-compete agreements 2 5 $ 38 For the years ended December 31, 2022, December 25, 2021 and December 26, 2020, there were no material adjustments recorded in our consolidated balance sheets relating to accounting for acquisitions incomplete in prior periods. At December 25, 2021 we recorded an estimated contingent consideration receivable of $ 5 million, which was subsequently increased by additional $ 5 million during 2022 based on delays in timing of government approval of a certain product. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020 we incurred $ 9 million, $ 7 million and $ 6 million in acquisition costs reported within income from continuing operations. Divestiture In the third quarter of 2021 we received contingent proceeds of $ 10 million from the 2019 sale of Hu-Friedy, resulting in the recognition of an additional after-tax gain of $ 7 million. During the fourth quarter of 2020 we received contingent proceeds of $ 2 million from the 2019 sale of Hu-Friedy, resulting in the recognition of an additional after-tax gain of $ 2 million. We do expect to receive any additional proceeds from the sale of Hu-Friedy.

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 5 – Property and Equipment, Net Property and equipment, including related estimated useful lives, consisted of the following: December 31, December 25, 2022 2021 Land $ 20 $ 21 Buildings and permanent improvements 135 140 Leasehold improvements 94 98 Machinery and warehouse equipment 169 153 Furniture, fixtures and other 127 119 Computer equipment and software 411 385 956 916 Less accumulated depreciation (573) (550) Property and equipment, net $ 383 $ 366 Estimated Useful Lives (in years) Buildings and permanent improvements 40 Machinery and warehouse equipment 5 - 10 Furniture, fixtures and other 3 - 10 Computer equipment and software 3 - 10 Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Property and equipment related depreciation expense for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 was $ 68 million, $ 71 million and $ 64 million, respectively.

Leases	12 Months Ended
Leases	Dec. 31, 2022
Leases [Abstract]
Leases	Note 6 – Leases We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment. Our leases have remaining terms of less than one year to approximately 19 years, some of which may include options to extend the leases for up to 15 years. The components of lease expense were as follows: Years Ended December 31, December 25, December 26, 2022 2021 2020 Operating lease cost: (1) (2) $ 150 $ 103 $ 87 Finance lease cost: Amortization of right-of-use assets 3 3 2 Total finance lease cost $ 3 $ 3 $ 2 (1) Includes variable lease expenses. (2) Operating lease cost for the years ended December 31, 2022, December 25, 2021, and December 26, 2020, include accelerated amortization of right-of-use assets of $ 42 million, $ 0 million and $ 0 million, respectively, related to facility leases recorded in “Restructuring and integration costs” within our consolidated statements of income. Further, for the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recognized impairment of right-of-use assets of $ 3 million, $ 0 million, and $ 4 million respectively, related to facility leases recorded in “Restructuring and integration costs” within our consolidated statement of income. Supplemental balance sheet information related to leases is as follows: Years Ended December 31, December 25, 2022 2021 Operating Leases: Operating lease right-of-use assets $ 284 $ 325 Current operating lease liabilities 73 76 Non-current operating lease liabilities 275 268 Total operating lease liabilities $ 348 $ 344 Finance Leases: Property and equipment, at cost $ 16 $ 13 Accumulated depreciation (6) (5) Property and equipment, net of accumulated depreciation $ 10 $ 8 Current maturities of long-term debt $ 4 $ 3 Long-term debt 6 4 Total finance lease liabilities $ 10 $ 7 Weighted Average Remaining Lease Term in Years: Operating leases 6.7 7.3 Finance leases 3.1 3.6 Weighted Average Discount Rate: Operating leases 2.8 % 2.4 % Finance leases 3.3 % 1.7 % Supplemental cash flow information related to leases is as follows: Years Ended December 31, December 25, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 87 85 Financing cash flows for finance leases 3 3 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 88 121 Finance leases 6 4 Maturities of lease liabilities are as follows: December 31, 2022 Operating Finance Leases Leases 2023 $ 82 $ 5 2024 66 3 2025 56 1 2026 46 1 2027 33 - Thereafter 98 1 Total future lease payments 381 11 Less imputed interest (33) (1) Total $ 348 $ 10 As of December 31, 2022, we have additional operating leases with total lease payments of $ 8 million for buildings and vehicles that have not yet commenced. These operating leases will commence subsequent to December 31, 2022, with lease terms of two years to five years . Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These leases are classified as operating leases and have a remaining lease term ranging from 4 months to 9 years . As of December 31, 2022, current and non-current liabilities associated with related party operating leases were $ 4 million and $ 14 million, respectively. Related party leases represented 5.0 % and 5.3 % of the total current and non- current operating lease liabilities, respectively. The present value of lease payments under these related party leases is not material to our consolidated financial statements.

Goodwill and Other Intangibles, Net	12 Months Ended
Goodwill and Other Intangibles, Net	Dec. 31, 2022
Goodwill and Other Intangibles, Net [Abstract]
Goodwill and Other Intangibles, Net	Note 7 – Goodwill and Other Intangibles, Net The changes in the carrying amount of goodwill for the years ended December 31, 2022 and December 25, 2021 were as follows: Health Care Distribution Technology and Value-Added Services Total Balance as of December 26, 2020 $ 1,501 $ 1,003 $ 2,504 Adjustments to goodwill: Acquisitions 359 24 383 Foreign currency translation (29) (4) (33) Balance as of December 25, 2021 1,831 1,023 2,854 Adjustments to goodwill: Acquisitions 86 (1) 85 Impairment (20) - (20) Foreign currency translation (22) (4) (26) Balance as of December 31, 2022 $ 1,875 $ 1,018 $ 2,893 For the year ended December 31, 2022, we recorded a $ 20 million impairment of goodwill relating to the disposal of an unprofitable business whose estimated fair value was lower than its carrying value. The disposal of this business is part of our restructuring initiative as more fully discussed in Other intangible assets consisted of the following: December 31, 2022 December 25, 2021 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Customer lists and relationships $ 826 $ (387) $ 439 $ 853 $ (353) $ 500 Trademarks / trade names - definite lived 125 (51) 74 129 (44) 85 Product Development 90 (56) 34 114 (70) 44 Non-compete agreements 25 (6) 19 25 (6) 19 Other 31 (10) 21 28 (8) 20 Total $ 1,097 $ (510) $ 587 $ 1,149 $ (481) $ 668 Trademarks, trade names, customer lists and customer relationships were established through business acquisitions. Definite-lived trademarks and trade names are amortized on a straight-line basis over a weighted-average period of approximately 8.4 years as of December 31, 2022. Customer lists and customer relationships are definite-lived intangible assets that are amortized on a straight-line basis over a weighted-average period of approximately 10.0 years as of December 31, 2022. Product development is a definite-lived intangible asset that is amortized on a straight-line basis over a weighted-average period of approximately 8.6 years as of December 31, 2022. Non-compete agreements represent amounts paid primarily to prior owners of acquired businesses, as well as certain sales persons, in exchange for placing restrictions on their ability to pose a competitive risk to us. Such amounts are amortized, on a straight-line basis over the respective non-compete period, which generally commences upon termination of employment or separation from us. The weighted-average non-compete period for agreements currently being amortized was approximately 5.3 years as of December 31, 2022. Amortization expense, excluding impairment charges, related to definite-lived intangible assets for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 was $ 126 million, $ 124 million and $ 106 million. During the year ended December 31, 2022, we recorded $ 49 million of impairment charges related to businesses within our health care distribution segment, represented by an intangible asset impairment of $ 15 million related to the disposal of an unprofitable business and a $ 34 million impairment of customer lists and relationships attributable to customer attrition rates being higher than expected in certain other businesses. Our impairment loss was calculated as the difference between the carrying value and the estimated fair value of the intangible assets, using a discounted estimate of future cash flows. During the year ended December 25, 2021, we recorded a $ 1 million impairment charge related ratably to a business within our health care distribution segment and a business within our technology and value-added services segment. During the year ended December 26, 2020, we recorded a $ 20 million impairment charge related to businesses within our technology and value-added services segment due to customer attrition rates being higher than expected. The above intangible asset impairment charges were recorded within selling, general and administrative expenses; and restructuring and integration charges in our consolidated statement of income. The annual amortization expense expected to be recorded for existing intangibles assets for the years 2023 through 2027 is $ 120 million, $ 96 million, $ 84 million, $ 68 million and $ 55 million.

Investments and Other	12 Months Ended
Investments and Other	Dec. 31, 2022
Investments And Other [Abstract]
Investments and Other	Note 8 – Investments and Other Investments and other consisted of the following: December 31, December 25, 2022 2021 Investment in unconsolidated affiliates $ 161 $ 168 Non-current deferred foreign, state and local income taxes 88 35 Notes receivable (1) 28 36 Capitalized costs for software to be sold, leased or marketed to external users 79 65 Security deposits 3 2 Acquisition-related indemnification 59 66 Non-current pension assets 8 - Other long-term assets 46 52 Total $ 472 $ 424 (1) Long-term notes receivable carry interest rates ranging from 3.0 % to 7.5 % and are due in varying installments through May 11, 2028 . Amortization expense, primarily related to capitalized costs for software to be sold, leased or marketed to external users, for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 was $ 18 million, $ 15 million and $ 16 million, respectively.

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 9 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable. Certain of our notes receivable contain variable interest rates. We believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Debt The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is classified as Level 3 within the fair value hierarchy, and as of December 31, 2022 and December 25, 2021 was estimated at $ 1,149 million and $ 873 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified SERP and our DCP. The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. Total Return Swaps The fair value for the Total Return Swap is measured by valuing the underlying ETFs of the swap using market-on- close pricing by industry providers as of the valuation date and are classified within Level 2 of the fair value hierarchy. Redeemable noncontrolling interests The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. Assets measured on a non-recurring basis at fair value include Goodwill and Other intangibles, net, and are classified as Level 3 within the fair value hierarchy. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2022 and December 25, 2021: December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return swaps - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576 December 25, 2021 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 8 $ - $ 8 Derivative contracts undesignated - 1 - 1 Total return swap - 1 - 1 Total assets $ - $ 10 $ - $ 10 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 3 $ - $ 3 Redeemable noncontrolling interests $ - $ - $ 613 $ 613

Concentrations of Risk	12 Months Ended
Concentrations of Risk	Dec. 31, 2022
Concentrations of Risk [Abstract]
Concentrations of Risk	Note 10 – Concentrations of Risk Certain financial instruments potentially subject us to concentrations of credit risk. These financial instruments consist primarily of cash equivalents, trade receivables, long-term investments, notes receivable and derivative instruments. In all cases, our maximum exposure to loss from credit risk equals the gross fair value of the financial instruments. We routinely maintain cash balances at financial institutions in excess of insured amounts. We have not experienced any loss in such accounts and we manage this risk through maintaining cash deposits and other highly liquid investments in high quality financial institutions. We continuously assess the need for reserves for such losses, which have been within our expectations. We do not require collateral or other security to support financial instruments subject to credit risk, except for long-term notes receivable. We limit our credit risk with respect to our cash equivalents, short-term and long-term investments and derivative instruments, by monitoring the credit worthiness of the financial institutions who are the counter-parties to such financial instruments. As a risk management policy, we limit the amount of credit exposure by diversifying and utilizing numerous investment grade counter-parties. With respect to our trade receivables, our credit risk is somewhat limited due to a relatively large customer base and its dispersion across different types of health care professionals and geographic areas. No single customer accounted for more than 2 % of our net sales in 2022 or 2021. With respect to our sources of supply, our top 10 health care distribution suppliers and our single largest supplier accounted for approximately 28 % and 4 %, respectively, of our aggregate purchases in each of the years ended December 31, 2022 and December 25, 2021. Our long-term notes receivable primarily represent strategic financing arrangements with certain affiliates. Generally, these notes are secured by certain assets of the counterparty; however, in most cases our security is subordinate to other commercial financial institutions. While we have exposure to credit loss in the event of non- performance by these counter-parties, we conduct ongoing assessments of their financial and operational performance.

Derivatives and Hedging Activities	12 Months Ended
Derivatives and Hedging Activities	Dec. 31, 2022
Derivatives and Hedging Activities [Abstract]
Derivatives and Hedging Activities	Note 11 – Derivatives and Hedging Activities We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and each other, and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital. During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S. dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Gains and losses related to these net investment hedges are recorded in accumulated other comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our consolidated statements of income. The aggregate notional value of this net investment hedge, which matures on November 16, 2023 , is approximately € 200 million. During the years ended December 31, 2022 and December 25, 2021, we recorded losses of $ 9 million and $ 11 million, respectively, within other comprehensive income related to these foreign currency forward contracts. On March 20, 2020 , we entered into a total return swap for the purpose of economically hedging our unfunded non- qualified SERP and our DCP. This swap will offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these plans was $ 43 million. At December 31, 2022, the notional value of the investments in these plans was $ 78 million. At December 31, 2022, the financing blended rate for this swap was based on the Secured Overnight Financing Rate (“SOFR”) of 4.03 % plus 0.55 %, for a combined rate of 4.58 %. For the years ended December 31, 2022 and December 25, 2021, we have recorded a gain/(loss), within selling, general and administrative in our consolidated statement of income, of approximately ($ 17 ) million and $ 12 million, respectively, net of transaction costs, related to this undesignated swap. During the years ended December 31, 2022 and December 25, 2021, the swap resulted in a neutral impact to our results of operations. This swap is expected to be renewed on an annual basis after its current expiration date of March 31, 2023, and is expected to result in a neutral impact to our results of operations. Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Amounts related to our hedging activities are recorded in prepaid expenses and other and/or accrued expenses: other within our consolidated balance sheets. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC 815 have been omitted.

Debt	12 Months Ended
Debt	Dec. 31, 2022
Debt [Abstract]
Debt	Note 12 – Debt Bank Credit Lines Bank credit lines consisted of the following: December 31, December 25, 2022 2021 Revolving credit agreement $ - $ - Other short-term bank credit lines 103 51 Total $ 103 $ 51 Revolving Credit Agreement On August 20, 2021 , we entered into a $ 1.0 billion revolving credit agreement (the “Credit Agreement”). This facility which matures on August 20, 2026 replaced our $ 750 million revolving credit facility which was scheduled to mature in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. Most LIBOR rates have been discontinued after December 31, 2021, while the remaining LIBOR rates will be discontinued immediately after June 30, 2023. We do not expect the discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our financial position or to materially affect our interest expense. The Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of December 31, 2022 and December 25, 2021, we had no borrowings under this revolving credit facility. As of December 31, 2022 and December 25, 2021, there were $ 9 million and $ 9 million of letters of credit, respectively, provided to third parties under the credit facility. Other Short-Term Bank Credit Lines As of December 31, 2022 and December 25, 2021, we had various other short-term bank credit lines available, with a maximum borrowing capacity of $ 402 million as of December 31, 2022, of which $ 103 million and $ 51 million, respectively, were outstanding. At December 31, 2022 and December 25, 2021, borrowings under all of these credit lines had a weighted average interest rate of 10.11 % and 10.44 %, respectively. Long-term debt Long-term debt consisted of the following: December 31, December 25, 2022 2021 Private placement facilities $ 699 $ 706 U.S. trade accounts receivable securitization 330 105 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 3.50 % at December 31, 2022 and ranging from 2.62 % to 4.27 % at December 25, 2021 7 4 Finance lease obligations 10 7 Total 1,046 822 Less current maturities (6) (11) Total long-term debt $ 1,040 $ 811 Private Placement Facilities Our private placement facilities were amended on October 20, 2021 to include four (previously three) insurance companies, have a total facility amount of $ 1.5 billion (previously $ 1.0 billion), and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through October 20, 2026 (previously June 23, 2023 ). The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years ). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. On March 5, 2021, we amended the private placement facilities to, among other things, (a) modify the financial covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum maintenance total leverage ratio to 3.25 x and remove the 1.00 % interest rate increase triggered if the net leverage ratio were to exceed 3.0 x. The components of our private placement facility borrowings, which have a weighted average interest rate of 2.99 %, as of December 31, 2022 are presented in the following table: Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 Less: Deferred debt issuance costs (1) Total $ 699 U.S. Trade Accounts Receivable Securitization We have a facility agreement based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . On December 15, 2022, we extended the expiration date of this facility agreement to December 15, 2025 (the previous maturity date was October 18, 2024 ) and maintained the purchase limit under the facility as $ 450 million with two banks as agents. As of December 31, 2022 and December 25, 2021, the borrowings outstanding under this securitization facility were $ 330 million and $ 105 million, respectively. At December 31, 2022, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 4.58 % plus 0.75 %, for a combined rate of 5.33 %. At December 25, 2021, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.19 % plus 0.75 %, for a combined rate of 0.94 %. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization. As of December 31, 2022, the aggregate amounts of long-term debt, including finance lease obligations and net of deferred debt issuance costs of $ 1 million, maturing in each of the next five years and thereafter are as follows: 2023 $ 6 2024 109 2025 331 2026 - 2027 100 Thereafter 500 Total $ 1,046

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2022
Income Taxes [Abstract]
Income Taxes	Note 13 – Income Taxes Income before taxes and equity in earnings of affiliates was as follows: Years ended December 31, December 25, December 26, 2022 2021 2020 Domestic $ 506 $ 593 $ 431 Foreign 215 238 69 Total $ 721 $ 831 $ 500 The provisions for income taxes were as follows: Years ended December 31, December 25, December 26, 2022 2021 2020 Current income tax expense: U.S. Federal $ 150 $ 129 $ 83 State and local 49 37 24 Foreign 44 43 41 Total current 243 209 148 Deferred income tax expense (benefit): U.S. Federal (48) (12) (18) State and local (13) (3) (5) Foreign (12) 4 (30) Total deferred (73) (11) (53) Total provision $ 170 $ 198 $ 95 The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows: Years Ended December 31, December 25, 2022 2021 Deferred income tax asset: Net operating losses and other carryforwards $ 64 $ 55 Inventory, premium coupon redemptions and accounts receivable valuation allowances 57 46 Stock-based compensation 11 13 Uniform capitalization adjustment to inventories 11 10 Operating lease liability 77 79 Other asset 48 41 Total deferred income tax asset 268 244 Valuation allowance for deferred tax assets (1) (36) (36) Net deferred income tax asset 232 208 Deferred income tax liability Intangibles amortization (112) (134) Operating lease right-of-use asset (61) (74) Property and equipment (7) (7) Total deferred tax liability (180) (215) Net deferred income tax asset (liability) $ 52 $ (7) (1) Primarily relates to operating losses, the benefits of which are uncertain. Any future reductions of such valuation allowances will be reflected as a reduction of income tax expense. The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting rules is judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes reversals of deferred tax liabilities and projected future taxable income. Since this evaluation requires consideration of events that may occur some years into the future, there is an element of judgment involved. Realization of our deferred tax assets is dependent on generating sufficient taxable income in future periods. We believe that it is more likely than not that future taxable income will be sufficient to allow us to recover substantially all of the value assigned to our deferred tax assets. However, if future events cause us to conclude that it is not more likely than not that we will be able to recover the value assigned to our deferred tax assets, we will be required to adjust our valuation allowance accordingly. As of December 31, 2022, we had federal, state and foreign net operating loss carryforwards of approximately $ 30 million, $ 31 million and $ 220 million, respectively. The federal, state and foreign net operating loss carryforwards will begin to expire in various years from 2023 through 2041. The amounts of federal, state and foreign net operating losses that can be carried forward indefinitely are $ 21 million, $ 4 million and $ 218 million, respectively. Years ended December 31, December 25, December 26, 2022 2021 2020 Income tax provision at federal statutory rate $ 151 $ 175 $ 105 State income tax provision, net of federal income tax effect 20 21 13 Foreign income tax provision 4 6 - Pass-through noncontrolling interest (4) (4) (3) Valuation allowance (2) (6) 1 Unrecognized tax benefits and audit settlements 11 7 (18) Interest expense related to loans (12) (11) (11) Tax benefit related to legal entity reorganization outside the U.S. - - (6) Other 2 10 14 Total income tax provision $ 170 $ 198 $ 95 For the year ended December 31, 2022, our effective tax rate was 23.5 %, compared to 23.8 % for the prior year period. In 2022, the difference between our effective tax rate and the federal statutory tax rate primarily relates to state and foreign income taxes and interest expense. In 2021, the difference between our effective tax rate and the federal statutory tax rate was primarily due to state and foreign income taxes and interest expense. In 2020, our effective tax rate was 19.1 %. The difference between our effective tax rate and the federal statutory tax rate was primarily due to an Advance Pricing Agreement with the U.S Internal Revenue Service (the “IRS”) in the U.S., other audit resolutions, state and foreign income taxes and interest expense. On August 16, 2022, the Inflation Reduction Act (H.R. 5376) (“IRA”) was signed into law in the United States. Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022 and levies a 1% excise tax on net stock repurchases after December 31, 2022. We are still in the process of analyzing the provisions of the IRA. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act includes, but is not limited to, certain income tax provisions that modify the Section 163(j) limitation of business interest and net operating loss carryover and carryback rules. The modifications to Section 163(j) increase the allowable business interest deduction from 30 % of adjusted taxable income to 50 % of adjusted taxable income for years beginning in 2019 and 2020. The CARES Act eliminated the NOL income limitation for years beginning before 2021 and it extended the carryback period to five years for losses incurred in 2018, 2019 and 2020. We have analyzed the income tax provisions of the CARES Act and have accounted for the impact in the year ended December 26, 2020, which did not have a material impact on our consolidated financial statements. There are certain other non-income tax benefits available to us under the CARES Act that require further clarification or interpretation that may affect our consolidated financial statements in the future. On December 27, 2020, the Consolidated Appropriations Act was enacted into law and extended certain non-income tax benefits under the CARES Act. On July 20, 2020, the IRS issued final regulations related to the Tax Cuts and Jobs Act enacted in 2017 (the “Tax Act”). The final regulations concern the global intangible low-taxed income (“GILTI”) and subpart F income provisions of the Tax Act. To provide flexibility to taxpayers, the IRS is permitting the application of these final regulations to prior tax years, if the taxpayer elects to do so. We have analyzed the final regulations, which do not have a material impact to our consolidated financial statements. On December 22, 2017, the U.S. government passed the Tax Act, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. Within our consolidated balance sheets, transition tax of $ 19 million and $ 14 million were included in “accrued taxes” for 2022 and 2021, respectively, and $ 23 million and $ 42 million were included in “other liabilities” for 2022 and 2021, respectively. Due to the one-time transition tax and the imposition of the GILTI provisions, all previously unremitted earnings will no longer be subject to U.S. federal income tax; however, there could be U.S., state and/or foreign withholding taxes upon distribution of such unremitted earnings. Determination of the amount of unrecognized deferred tax liability with respect to such earnings is not practicable. ASC 740 prescribes the accounting for uncertainty in income taxes recognized in the financial statements in accordance with other provisions contained within this guidance. This topic prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by the taxing authorities. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likely of being realized upon ultimate audit settlement. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities for uncertain tax positions taken in respect of certain tax matters. The total amount of unrecognized tax benefits, which are included in “other liabilities” within our consolidated balance sheets, as of December 31, 2022 and December 25, 2021 was approximately $ 94 million and $ 84 million, respectively, of which $ 80 million and $ 69 million, respectively would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our consolidated statements of income. All tax returns audited by the IRS are officially closed through 2018. The tax years subject to examination by the IRS include years 2019 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS examination. During the quarter ended December 25, 2021, we were notified by the IRS that tax year 2019 was selected for examination. During the quarter ended June 26, 2021 we reached a resolution with the Appellate Division for all remaining outstanding issues for 2012 and 2013. During the quarter ended September 26, 2020 we reached an agreement with the Advanced Pricing Division on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution was to mitigate future transfer pricing audit adjustments. In the fourth quarter of 2020, we reached a resolution with the IRS for the 2014-2016 audit cycle. The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense (credit) was approximately $ 0 million, $ 0 million and $( 3 ) million in 2022, 2021 and 2020, respectively. The total amount of accrued interest is included in “other liabilities”, and was approximately $ 12 million as of December 31, 2022 and $ 12 million as of December 25, 2021. The amount of penalties accrued for during the periods presented were not material to our consolidated financial statements. The following table provides a reconciliation of unrecognized tax benefits: December 31, December 25, December 26, 2022 2021 2020 Balance, beginning of period $ 71 $ 70 $ 91 Additions based on current year tax positions 14 3 5 Additions based on prior year tax positions 8 11 8 Reductions based on prior year tax positions - (1) (1) Reductions resulting from settlements with taxing authorities (1) (9) (19) Reductions resulting from lapse in statutes of limitations (10) (3) (14) Balance, end of period $ 82 $ 71 $ 70

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Plans of Restructuring and Integration Costs	12 Months Ended
Plans of Restructuring and Integration Costs	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Plans of Restructuring	Note 14 – Plans of Restructuring On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the strategic plan and streamlining operations and other initiatives to increase efficiency. We expect this initiative to extend through 2023. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. During the year ended December 31, 2022, we recorded restructuring charges of $ 128 million primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets, impairment of other long-lived assets and lease exit costs. During the three months ended December 31, 2022, in connection with our restructuring plan, we vacated one of the buildings at our corporate headquarters in Melville NY, which resulted in an accelerated amortization of right- of-use lease asset of $ 34 million. We also initiated the disposal of a non-profitable US business and recorded related costs of $ 49 million which primarily consisted of impairment of intangible assets and goodwill, inventory impairment, and severance and employee-related costs. These expenses are included in the $ 128 million of restructuring charges discussed above. The disposal is expected to be completed in the first quarter of 2023. On August 26, 2022, we acquired Midway Dental Supply. In connection with this acquisition, during the year ended December 31, 2022, we recorded integration costs of $ 3 million related to one-time employee and other costs, as well as restructuring charges of $ 9 million, which are included in the $ 128 million of restructuring charges discussed above. On November 20, 2019, we committed to a contemplated restructuring initiative intended to mitigate stranded costs associated with the spin-off of our animal health business and to rationalize operations and provide expense efficiencies. These activities were originally expected to be completed by the end of 2020 but we extended them to the end of 2021 in light of the changes to the business environment brought on by the COVID-19 pandemic. The restructuring activities under this prior initiative were completed in 2021. Restructuring and integration costs recorded during our 2022, 2021 and 2020 fiscal years consisted of the following: Year Ended December 31, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 25 $ - $ 4 $ - $ 29 Impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets 47 - - - 47 Exit and other related costs 3 - - - 3 Loss on disposal of a business 49 - 49 Integration employee-related and other costs - 3 - - 3 Total restructuring and integration costs $ 124 $ 3 $ 4 $ - $ 131 Year Ended December 25, 2021 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 6 $ - $ 2 $ - $ 8 Total restructuring and integration costs $ 6 $ - $ 2 $ - $ 8 Year Ended December 26, 2020 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 25 $ - $ 1 $ - $ 26 Impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets 4 - - - 4 Exit and other related costs 2 - - - 2 Total restructuring and integration costs $ 31 $ - $ 1 $ - $ 32 The following table summarizes, by reportable segment, the activity related to the liabilities associated with our restructuring initiatives for the year ended December 31, 2022. The remaining accrued balance of restructuring costs as of December 31, 2022 is included in accrued expenses: other within our condensed consolidated balance sheet. Technology and Health Care Value-Added Distribution Services Total Balance, December 25, 2021 $ 3 $ 1 $ 4 Restructuring charges 124 4 128 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (47) - (47) Non-cash impairment on disposal of a business (46) - (46) Cash payments and other adjustments (13) (2) (15) Balance, December 31, 2022 $ 21 $ 3 $ 24

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Purchase Commitments In our health care distribution business, we sometimes enter into long-term purchase commitments to ensure the availability of products for distribution. Future minimum annual payments for inventory purchase commitments as of December 31, 2022 were: 2023 $ 5 2024 4 2025 4 2026 4 2027 4 Thereafter - Total minimum inventory purchase commitment payments $ 21 Employment, Consulting and Non-Compete Agreements We have employment, consulting and non-compete agreements that have varying base aggregate annual payments for the years 2023 through 2027 and thereafter of approximately $ 23 million, $ 7 million, $ 5 million, $ 0 million, $ 0 million, and $ 0 million, respectively. We also have lifetime consulting agreements that provide for current compensation of four-hundred thousand dollars per year, increasing twenty-five thousand dollars every fifth year with the next increase in 2026. In addition, some agreements have provisions for additional incentives and compensation. Litigation Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one- hundred and fifty ( 150 ); in approximately half of those cases one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its affiliated companies) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following cases are set for trial: the action filed by DCH Health Care Authority, et al. in Alabama state court, which has been designated a bellwether with eight of thirty-eight plaintiffs set for a jury trial on July 24, 2023; and the action filed by Florida Health Sciences Center, Inc. (and 38 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in October 2024. In December 2022, we settled seven cases filed in Utah (plus one case in which we were not yet named a defendant) by nineteen plaintiffs for a total amount of sixty thousand dollars. The seven cases have been dismissed. Of Henry Schein’s 2022 net sales of approximately $ 12.6 billion from continuing operations, sales of opioids represented less than two-tenths of 1 percent . Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia, seeking documents in connection with an investigation of possible violations of the Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia. The October Subpoena seeks documents relating to payments Henry Schein received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the investigation. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of December 31, 2022, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Stock Based Compensation	12 Months Ended
Stock Based Compensation	Dec. 31, 2022
Stock Based Compensation [Abstract]
Stock Based Compensation	Note 16 – Stock-Based Compensation Stock-based awards are provided to certain employees under the terms of our 2020 Stock Incentive Plan and to non-employee directors under the terms of our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”). However, for our 2021 fiscal year, in light of the COVID-19 pandemic, the Compensation Committee determined it would be difficult for management to set a meaningful three-year cumulative earnings per share target as the goal applicable to performance-based RSU awards as it had done in prior years. Instead, the Compensation Committee set our equity-based awards to employees for fiscal 2021 in the form of time-based RSUs and non-qualified stock options which focus on stock value appreciation and retention instead of pre-established performance goals. Our non-employee directors continued to receive equity-based awards for fiscal 2021 solely in the form of time-based RSUs. In March 2022, the Compensation Committee reinstated performance-based RSUs for equity-based awards to employees for fiscal 2022 and awarded grants in the form of performance-based RSUs, time-based RSUs and non-qualified stock options. As of December 31, 2022, there were 70,942,657 shares authorized and 8,034,696 shares available to be granted under the 2020 Stock Incentive Plan and 1,892,657 shares authorized and 192,400 shares available to be granted under the 2015 Non-Employee Director Stock Incentive Plan. RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that primarily vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. RSUs granted under the 2015 Non-Employee Director Stock Incentive Plan primarily are granted with 12 -month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line basis. With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing stock price at the time of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant. Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2020 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital transactions referred to above), restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact of certain products and unforeseen events or circumstances affecting us. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans. Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price following vesting of the stock options. Stock options are granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued beginning in 2021 vest one-third per year based on the recipient’s continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of the term upon certain events. Compensation expense for these stock options is recognized using a graded vesting method. We estimate the fair value of stock options using the Black-Scholes valuation model. In addition to equity-based awards granted in fiscal 2021 under the long-term incentive program, the Compensation Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive Plan to recipients of performance-based RSUs under the 2018 long-term incentive program. The payout under the performance-based restricted stock units granted under the fiscal 2018 long-term incentive program (the “2018 LTIP”) was negatively impacted by the global COVID-19 pandemic. Given the significance of the impact of the pandemic on our three - year EPS goal under such equity awards and the contributions made by our employees (including those who received such awards), on March 3, 2021, the Compensation Committee granted a Special Pandemic Recognition Award to recipients of performance-based restricted stock units under the 2018 LTIP who were employed by us on the grant date of the Special Pandemic Recognition Award. These time-based RSU awards vest 50 % on the first anniversary of the grant date and 50 % on the second anniversary of the grant date, based on the recipient’s continued service and subject to the terms and conditions of the 2020 Stock Incentive Plan, and are recorded as compensation expense using a graded vesting method. The combination of the 20 % payout based on actual performance of the 2018 LTIP and the one-time Special Pandemic Recognition Award granted in 2021 will generate a cumulative payout of 75 % of each recipient’s original number of performance-based restricted stock units awarded in 2018 if the recipient satisfies the two -year vesting schedule commencing on the grant date. Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $ 54 million ($ 41 million after-tax), $ 78 million ($ 60 million after-tax) and $ 9 million ($ 7 million after-tax) for the years ended December 31, 2022, December 25, 2021 and December 26, 2020. Total unrecognized compensation cost related to non-vested awards as of December 31, 2022 was $ 75 million, which is expected to be recognized over a weighted-average period of approximately 2.1 years. The weighted-average grant date fair value of stock-based awards granted before forfeitures was $ 85.51 , $ 62.72 and $ 60.23 per share during the years ended December 31, 2022, December 25, 2021 and December 26, 2020. Certain stock-based compensation granted may require us to settle in the form of a cash payment. During the year ended December 31, 2022, we recorded a liability of $ 0.4 million relating to the grant date fair value of stock-based compensation to be settled in cash. We record deferred income tax assets for awards that will result in future deductions on our income tax returns based on the amount of compensation cost recognized and our statutory tax rate in the jurisdiction in which we will receive a deduction. Our accompanying consolidated statements of cash flows present our stock-based compensation expense as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, there were no benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the years ended December 31, 2022, December 25, 2021 and December 26, 2020. The following weighted-average assumptions were used in determining the most recent fair values of stock options using the Black-Scholes valuation model: 2022 Expected dividend yield 0.00 % Expected stock price volatility 27.80 % Risk-free interest rate 3.62 % Expected life of options (years) 6.00 We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The six -year expected life of the options was determined using the simplified method for estimating the expected term as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us. The following table summarizes the stock option activity for the year ended December 31, 2022: Stock Options Weighted Remaining Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life in Years Value Outstanding at beginning of year 767,717 $ 63.24 Granted 420,075 85.81 Exercised (36,150) 62.92 Forfeited (34,068) 74.84 Outstanding at end of year 1,117,574 $ 71.38 8.5 $ 12 Options exercisable at end of year 220,688 $ 63.35 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 885,428 $ 73.50 8.7 $ 8 The following tables summarize the activity of our unvested RSUs for the year ended December 31, 2022: Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,945,862 $ 58.79 674,753 $ 59.63 Granted 471,840 85.49 267,865 82.35 Vested (566,887) 55.46 (396,220) 59.21 Forfeited (94,771) 67.87 (25,482) 67.65 Outstanding at end of period 1,756,044 $ 66.59 $ 79.87 520,916 $ 60.23 $ 79.87 The total intrinsic value per share of RSUs that vested was $ 78.74 , $ 73.99 and $ 61.49 during the years ended December 31, 2022, December 25, 2021 and December 26, 2020.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2022
Employee Benefit Plans [Abstract]
Employee Benefit Plans	Note 17 – Employee Benefit Plans Defined benefit plans Certain of our employees in our international markets participate in various noncontributory defined benefit plans. These plans are managed to provide pension benefits to covered employees in accordance with local regulations and practices. Our net unfunded liability for these plans are recorded in accrued expenses: other; and other liabilities within our consolidated balance sheets. The following table presents the changes in projected benefit obligations, plan assets, and the funded status of our defined benefit pension plans: Years Ended December 31, December 25, 2022 2021 Obligation and funded status: Change in benefit obligation Projected benefit obligation, beginning of period $ 128 $ 130 Service costs 3 4 Interest cost 1 - Past service cost - 5 Actuarial loss (19) (5) Benefits paid (1) (1) - Participant contributions 1 1 Settlements (1) (2) Effect of foreign currency translation (4) (5) Projected benefit obligation, end of period $ 108 $ 128 Change in plan assets Fair value of plan assets at beginning of period $ 75 $ 65 Actual return on plan assets (3) 5 Employer contributions 2 2 Plan participant contributions 1 1 Expected return on plan assets 1 4 Benefit received (1) - 2 Settlements (1) (3) Effect of foreign currency translation (2) (1) Fair value of plan assets at end of period $ 73 $ 75 Unfunded status at end of period $ 35 $ 53 Includes regular benefit payments and amounts transferred in by new participants. The majority of our defined benefit plans are unfunded, with the exception of one plan in one country where the amount of assets exceeds the projected benefit obligation by approximately $ 6 million and $ 6 million as of December 31, 2022 and December 25, 2021, respectively. The following table provides the amounts recognized in our consolidated balance sheets for our defined benefit pension plans: Years Ended December 31, December 25, 2022 2021 Non-current assets $ 25 $ 22 Current liabilities (1) (1) Non-current liabilities (59) (74) Accumulated other comprehensive loss, pre-tax 4 21 The following table provides the net periodic pension cost for our defined benefit plans: Years Ended December 31, December 25, December 26, 2022 2021 2020 Service cost $ 3 $ 4 $ 3 Interest cost 1 - - Expected return on plan assets (1) (1) - Employee contributions - - - Amortization of prior service credit 1 1 1 Recognized net actuarial loss - - - Settlements - - - Net periodic pension cost $ 4 $ 4 $ 4 The following tables present the weighted-average actuarial assumptions used to determine our pension benefit obligation and our net periodic pension cost for the periods presented: Years Ended December 31, December 25, Pension Benefit Obligation 2022 2021 Weighted average discount rate 1.67 % 0.87 % Years Ended December 31, December 25, December 26, Net Periodic Pension Cost 2022 2021 2020 Discount rate-pension benefit 1.25 % 0.56 % 0.51 % Expected return on plan assets 0.81 % 0.71 % 0.87 % Rate of compensation increase 1.68 % 1.95 % 1.97 % Pension increase rate 0.61 % 0.72 % 0.67 % The following table presents the estimated pension benefit payments that are payable to the plan’s participants as of December 31, 2022: Year 2023 $ 6 2024 6 2025 5 2026 5 2027 7 2028 to 2032 38 Total $ 67 401(k) Plans We offer qualified 401(k) plans to substantially all our domestic full-time employees. As determined by our Board of Directors, matching contributions to these plans generally do not exceed 100 % of the participants’ contributions up to 7 % of their base compensation, subject to applicable legal limits. Matching contributions consist of cash and were allocated entirely to the participants’ investment elections on file, subject to a 20 % allocation limit to the Henry Schein Stock Fund. Due to the impact of COVID-19, as part of our initiative to generate cash savings, we suspended the matching contribution for the second half of 2020. The matching contribution was reinstated in 2021. Forfeitures attributable to participants whose employment terminates prior to becoming fully vested are used to reduce our matching contributions and offset administrative expenses of the 401(k) plans. Assets of the 401(k) and other defined contribution plans are held in self-directed accounts enabling participants to choose from various investment fund options. Matching contributions related to these plans charged to operations during the years ended December 31, 2022, December 25, 2021 and December 26, 2020 amounted to $ 45 million, $ 38 million and $ 21 million, respectively. Within our consolidated statements of income, $ 37 million is included in selling, general and administrative expenses; and $ 8 million is included in cost of goods sold. Supplemental Executive Retirement Plan (“SERP”) We offer an unfunded, non-qualified SERP to eligible employees. This plan generally covers officers and certain highly compensated employees after they have reached the maximum IRS allowed pre-tax 401(k) contribution limit. Our contributions to this plan are equal to the 401(k) employee-elected contribution percentage applied to base compensation for the portion of the year in which such employees are not eligible to make pre-tax contributions to the 401(k) plan. Due to the impact of COVID-19, as part of our initiative to generate cash savings, we suspended contributions under the SERP for the second half of 2020. Contributions to the SERP were restored in 2021. The amounts charged to operations during the years ended December 31, 2022, December 25, 2021 and December 26, 2020 amounted to $ (1) million, $ 2 million and $ 3 million, respectively. The charges are included in selling, general and administrative expenses line item within our consolidated statements of income. Deferred Compensation Plan (“DCP”) During 2011, we began to offer DCP to a select group of management or highly compensated employees of the Company and certain subsidiaries. This plan allows for the elective deferral of base salary, bonus and/or commission compensation by eligible employees. The amounts charged to operations during the years ended December 31, 2022, December 25, 2021 and December 26, 2020 were approximately $ (11) million, $ 8 million and $ 8 million, respectively. The charges are included in selling, general and administrative expenses line item within our consolidated statements of income.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Redeemable Noncontrolling Interests	12 Months Ended
Redeemable Noncontrolling Interests	Dec. 31, 2022
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 18 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. ASC 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 are presented in the following table: December 31, December 25, December 26, 2022 2021 2020 Balance, beginning of period $ 613 $ 328 $ 287 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (31) (60) (17) Increase in redeemable noncontrolling interests due to business acquisitions 4 189 28 Net income attributable to redeemable noncontrolling interests 21 23 14 Dividends declared (21) (21) (13) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (6) (6) (4) Change in fair value of redeemable securities (4) 160 33 Balance, end of period $ 576 $ 613 $ 328

Comprehensive Income	12 Months Ended
Comprehensive Income	Dec. 31, 2022
Comprehensive Income [Abstract]
Comprehensive Income	Note 19 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: December 31, December 25, December 26, 2022 2021 2020 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (37) $ (31) $ (25) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ - $ - Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (236) $ (155) $ (77) Unrealized gain (loss) from foreign currency hedging activities 5 (2) (11) Pension adjustment loss (2) (14) (20) Accumulated other comprehensive loss $ (233) $ (171) $ (108) Total Accumulated other comprehensive loss $ (271) $ (202) $ (133) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: December 31, December 25, December 26, 2022 2021 2020 Net income $ 566 $ 660 $ 420 Foreign currency translation gain (loss) (88) (84) 63 Tax effect - - - Foreign currency translation gain (loss) (88) (84) 63 Unrealized gain (loss) from foreign currency hedging activities 10 12 (10) Tax effect (3) (3) 3 Unrealized gain (loss) from foreign currency hedging activities 7 9 (7) Pension adjustment gain 16 8 - Tax effect (4) (2) - Pension adjustment gain 12 6 - Comprehensive income $ 497 $ 591 $ 476 Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the years ended December 31, 2022, December 25, 2021 and December 26, 2020 was primarily due to changes in foreign currency exchange rates of the Euro, British Pound, Australian Dollar, Brazilian Real, New Zealand Dollar and Canadian Dollar. The foreign currency translation gain (loss) during the years ended December 31, 2022, December 25, 2021 and December 26, 2020 was primarily attributable to a net investment hedge that was entered into during 2019. The following table summarizes our total comprehensive income, net of applicable taxes as follows: December 31, December 25, December 26, 2022 2021 2020 Comprehensive income attributable to Henry Schein, Inc. $ 476 $ 568 $ 463 Comprehensive income attributable to noncontrolling interests 6 6 3 Comprehensive income attributable to Redeemable noncontrolling interests 15 17 10 Comprehensive income $ 497 $ 591 $ 476

Discontinued Operations	12 Months Ended
Discontinued Operations	Dec. 31, 2022
Discontinued Operations [Abstract]
Discontinued Operations	Note 20 – Discontinued Operations Animal Health Spin-off On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus (“Merger Sub”). In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $ 1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors (the “Share Sale Investors”) for $ 361 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”). After the Share Sale and Animal Health Spin-off, Merger Sub consummated the Merger whereby it merged with and into Vets First Choice, with Vets First Choice surviving the Merger as a wholly owned subsidiary of Covetrus. Immediately following the consummation of the Merger, on a fully diluted basis, (i) approximately 63 % of the shares of Covetrus common stock were (a) owned by our stockholders and the Share Sale Investors, and (b) held by certain employees of the Henry Schein Animal Health Business (in the form of certain equity awards), and (ii) approximately 37 % of the shares of Covetrus common stock were (a) owned by stockholders of Vets First Choice immediately prior to the Merger, and (b) held by certain employees of Vets First Choice (in the form of certain equity awards). After the Separation and the Merger, we no longer beneficially owned any shares of Covetrus common stock and, following the Distribution Date, will not consolidate the financial results of Covetrus for the purpose of our financial reporting. Following the Separation and the Merger, Covetrus was an independent, publicly traded company on the Nasdaq Global Select Market. In connection with the completion of the Animal Health Spin-off, we entered into a transition services agreement, which ended in December 2020, with Covetrus under which we agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services. As a result of the Separation, the financial position and results of operations of the Henry Schein Animal Health Business are presented as discontinued operations and have been excluded from continuing operations and segment results for all periods presented. The accompanying notes to the consolidated financial statements have been revised to reflect the effect of the Separation and all prior year balances have been revised accordingly to reflect continuing operations only. The historical statements of Comprehensive Income (Loss) and Shareholders' Equity have not been revised to reflect the Separation and instead reflect the Separation as an adjustment to the balances at December 26, 2020. In February 2019, we completed the Animal Health Spin-off. During the year ended December 26, 2020, we incurred $ 0 million in transaction costs associated with this transaction. All transaction costs related to the Animal Health Spin-off have been included in results from discontinued operations. Summarized financial information for our discontinued operations is as follows: Year Ended December 26, 2020 Selling, general and administrative 2 Operating loss (2) Income tax benefit (3) Income from discontinued operations 1 Net income from discontinued operations attributable to Henry Schein, Inc. 1 The operating loss from discontinued operations for the year ended December 26, 2020 was primarily attributable to costs directly related to the Animal Health Spin-off. The net income from discontinued operations for the year ended December 26, 2020 was primarily attributable to a reduction in a liability for tax indemnification and a tax refund received during 2020 by a holding company previously part of our Animal Health legal structure and other favorable tax resolutions.

Earnings Per Share	12 Months Ended
Earnings Per Share	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Note 21 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted- average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Years Ended December 31, December 25, December 26, 2022 2021 2020 Basic 136,064,221 140,090,889 142,504,193 Effect of dilutive securities: Stock options and restricted stock units 1,691,449 1,681,892 899,489 Diluted 137,755,670 141,772,781 143,403,682 The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows: Years Ended December 31, December 25, December 26, 2022 2021 2020 Stock options 342,716 611,869 - Restricted stock units 19,466 1,048 2,398 Total anti-dilutive securities excluded from EPS computation 362,182 612,917 2,398

Supplemental Cash Flow Information	12 Months Ended
Supplemental Cash Flow Information	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Note 22 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Years ended December 31, December 25, December 26, 2022 2021 2020 Interest $ 47 $ 29 $ 43 Income taxes 265 242 207 For the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we had $ 10 million, $ 12 million and $ (10) million of non-cash net unrealized gains (losses) related to foreign currency hedging activities, respectively.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2022
Related Party Transactions
Related Party Transactions	Note 23 – Related Party Transactions In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, we entered into a transition services agreement with Covetrus under which we agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services. For the year ended December 26, 2020, we recorded approximately $ 13 million of fees for these services. Pursuant to the transition services agreement, Covetrus purchased certain products from us. During the year December 26, 2020, net sales to Covetrus under the transition services agreement were approximately $ 75 million. Sales to Covetrus under the transition services agreement ended in December 2020. In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $ 31 million annually for the use of their intellectual property. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded $ 31 million, $ 31 million and $ 31 million, respectively in connection with costs related to this royalty agreement. As of December 31, 2022 and December 25, 2021, Henry Schein One, LLC had a net receivable (payable) balance from (to) Internet Brands of ($ 8 ) million and $ 9 million, respectively, comprised of amounts related to results of operations and the royalty agreement. The components of this receivable and payable are recorded within prepaid expenses and other; and accrued expenses: other, respectively, within our consolidated balance sheets. During our normal course of business, we have interests in entities that we account for under the equity accounting method. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded net sales of $ 46 million, $ 48 million, and $ 38 respectively, to such entities. During our fiscal years ended 2022, 2021 and 2020, we purchased $ 9 million, $ 15 million and $ 12 million respectively, from such entities. At December 31, 2022 and December 25, 2021, we had in aggregate $ 36 million and $ 44 million, due from our equity affiliates, and $ 6 million and $ 7 million due to our equity affiliates, respectively. Certain of our facilities related to our acquisitions are leased from employees and minority shareholders.

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Basis of Presentation and Significant Accounting Policies [Abstract]
Nature of Operations	Nature of Operations We distribute health care products and services primarily to office-based dental and medical practitioners, across dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics and alternate care clinics. We also provide software, technology and other value- added services to health care practitioners. Our dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices and integrated delivery networks, among other providers across a wide range of specialties. We have operations or affiliates in the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, France, Germany, Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, Mexico, the Netherlands, New Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, United Arab Emirates and the United Kingdom.
Basis of Presentation	Basis of Presentation Our consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates in which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our consolidated financial condition, results of operations or cash flows. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At December 31, 2022 and December 25, 2021, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 327 million and $ 138 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 255 million and $ 105 million, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. Demand for these non-PPE products increased in the second half of 2020 and continued throughout the years ended December 25, 2021 and December 31, 2022, resulting in growth over the prior years. Demand for PPE products declined during the year ended December 31, 2022. Our consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time.
Fiscal Year	Fiscal Year We report our results of operations and cash flows on a 52 - 53 week basis ending on the last Saturday of December. The year ended December 31, 2022 consisted of 53 weeks, and the years ended, December 25, 2021 and December 26, 2020 consisted of 52 weeks.
Revenue Recognition	Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration that we expect to receive for those goods or services. To recognize revenue, we do the following: • identify the contract(s) with a customer; • identify the performance obligations in the contract; • determine the transaction price; • allocate the transaction price to the performance obligations in the contract; and • recognize revenue when, or as, the entity satisfies a performance obligation. We generate revenue from the sale of dental and medical consumable products, equipment (Health care distribution revenues), software products and services and other sources (Technology and value-added services revenues). Provisions for discounts, rebates to customers, customer returns and other contra revenue adjustments are included in the transaction price at contract inception by estimating the most likely amount based upon historical data and estimates and are provided for in the period in which the related sales are recognized. Revenue derived from the sale of consumable products is recognized at a point in time when control transfers to the customer. Such sales typically entail high-volume, low-dollar orders shipped using third-party common carriers. We believe that the shipment date is the most appropriate point in time indicating control has transferred to the customer because we have no post-shipment obligations and this is when legal title and risks and rewards of ownership transfer to the customer and the point at which we have an enforceable right to payment. Revenue derived from the sale of equipment is recognized when control transfers to the customer. This occurs when the equipment is delivered. Such sales typically entail scheduled deliveries of large equipment primarily by equipment service technicians. Most equipment requires minimal installation, which is typically completed at the time of delivery. Our product generally carries standard warranty terms provided by the manufacturer, however, in instances where we provide warranty labor services, the warranty costs are accrued in accordance with Accounting Standards Codification (“ASC”) 460 “Guarantees”. At December 31, 2022 and December 25, 2021, we had accrued approximately $ 8 million and $ 8 million, respectively, for warranty costs. Revenue derived from the sale of software products is recognized when products are delivered to customers or made available electronically. Such software is generally installed by customers and does not require extensive training due to the nature of its design. Revenue derived from post-contract customer support for software, including annual support and/or training, is generally recognized over time using time elapsed as the input method that best depicts the transfer of control to the customer. Revenue derived from software sold on Software-as-a - Service basis is recognized ratably over the subscription period as control is transferred to the customer. Revenue derived from other sources, including freight charges, equipment repairs and financial services, is recognized when the related product revenue is recognized or when the services are provided. We apply the practical expedient to treat shipping and handling activities performed after the customer obtains control as fulfillment activities, rather than a separate performance obligation in the contract. Sales, value-add and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Certain of our revenue is derived from bundled arrangements that include multiple distinct performance obligations, which are accounted for separately. When we sell software products together with related services (i.e., training and technical support), we allocate revenue to software using the residual method, using an estimate of the standalone selling price to estimate the fair value of the undelivered elements. Bundled arrangements that include elements that are not considered software consist primarily of equipment and the related installation service. We allocate revenue for such arrangements based on the relative selling prices of the goods or services. If an observable selling price is not available (i.e., we do not sell the goods or services separately), we use one of the following techniques to estimate the standalone selling price: adjusted market approach; cost-plus approach; or the residual method. There is no specific hierarchy for the use of these methods, but the estimated selling price reflects our best estimate of what the selling prices of each deliverable would be if it were sold regularly on a standalone basis taking into consideration the cost structure of our business, technical skill required, customer location and other market conditions. Sales Returns Sales returns are recognized as a reduction of revenue by the amount of expected returns and are recorded as refund liability within current liabilities. We estimate the amount of revenue expected to be reversed to calculate the sales return liability based on historical data for specific products, adjusted as necessary for new products. The allowance for returns is presented gross as a refund liability and we record an inventory asset (and a corresponding adjustment to cost of sales) for any products that we expect to be returned. Cost of Sales The primary components of cost of sales include the cost of the product (net of purchase discounts, supplier chargebacks and rebates) and inbound and outbound freight charges. Costs related to purchasing, receiving, inspections, warehousing, internal inventory transfers and other costs of our distribution network are included in selling, general and administrative expenses along with other operating costs. Total distribution network costs were $ 103 million, $ 89 million and $ 72 million for the years ended December 31, 2022, December 25, 2021 and December 26, 2020. Supplier Rebates Supplier rebates are included as a reduction of cost of sales and are recognized over the period they are earned. The factors we consider in estimating supplier rebate accruals include forecasted inventory purchases and sales, in conjunction with supplier rebate contract terms, which generally provide for increasing rebates based on either increased purchase or sales volume. Direct Shipping and Handling Costs Freight and other direct shipping costs are included in cost of sales. Direct handling costs, which represent primarily direct compensation costs of employees who pick, pack and otherwise prepare, if necessary, merchandise for shipment to our customers are reflected in selling, general and administrative expenses. Direct handling costs were $ 96 million, $ 97 million and $ 79 million for the years ended December 31, 2022, December 25, 2021 and December 26, 2020.
Advertising and Promotional Costs	Advertising and Promotional Costs We generally expense advertising and promotional costs as incurred. Total advertising and promotional expenses were $ 47 million, $ 48 million and $ 32 million for the years ended December 31, 2022, December 25, 2021 and December 26, 2020.
Stock Compensation Costs	Stock Compensation Costs We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period for time-based restricted stock units and on a graded vesting basis for the option awards. For performance-based awards, at each reporting date, we reassess whether achievement of the performance condition is probable and accrue compensation expense when achievement of the performance condition is probable. Our stock-based compensation expense is reflected in selling, general and administrative expenses.
Employment Benefit Plans and other Postretirement Benefit Plans	Employment Benefit Plans and other Postretirement Benefit Plans Certain of our employees in our international markets participate in various noncontributory defined benefit plans. We recognize the funded status, measured as the difference between the fair value of plan assets and the benefit obligation, of each applicable plan, within accumulated other comprehensive income in the consolidated balance sheets, whereby each unfunded plan is recognized as a liability and each funded plan is recognized as either an asset or liability based on its funded status. We measure our plan assets and liabilities at the end of our fiscal year. Net periodic pension costs and valuations are dependent on assumptions used by third-party actuaries in calculating those amounts. These assumptions include discount rates, expected return on plan assets, rate of future compensation levels, retirement rates, mortality rates, and other factors. We record the service cost component of net pension cost in selling, general and administrative expenses within our consolidated statements of income.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value. Outstanding checks in excess of funds on deposit of $ 54 million and $ 2 million, primarily related to payments for inventory, were classified as accounts payable as of December 31, 2022 and December 25, 2021.
Contract Balances	Contract Balances Contract balances represent amounts presented in our consolidated balance sheets when either we have transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets and contract liabilities. Accounts Receivable and Allowance for Credit Losses Accounts receivable are generally recognized when health care distribution and technology and value-added services revenues are recognized. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that we do not expect to collect. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. We record allowances for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided at differing rates, based upon the age of the receivable, the collection history associated with the geographic region that the receivable was recorded in, current economic trends and reasonable supportable forecasts. We write-off a receivable and charge it against its recorded allowance when we deem them uncollectible. Our allowance for doubtful accounts was $ 65 million, $ 67 million and $ 88 million as of December 31, 2022, December 25, 2021 and December 26, 2020, respectively. Additions to the allowance for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 were $ 8 million, $ 0 million and $ 36 million. Deductions to the allowance for the years ended December 31, 2022, December 25, 2021 and December 26, 2020 were $ 10 million, $ 21 million and $ 8 million. Contract Assets Contract assets include amounts related to any conditional right to consideration for work completed but not billed as of the reporting date, and generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to accounts receivable when the right becomes unconditional. The contract assets primarily relate to our bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current contract assets are included in Prepaid expenses and other and the non-current contract assets are included in investments and other within our consolidated balance sheets. Current and non-current contract asset balances as of December 31, 2022 and December 25, 2021 were not material. Contract Liabilities Contract liabilities are comprised of advance payments and upfront payments for service arrangements provided over time that are accounted for as deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in accrued expenses: Other and the non-current contract liabilities are included in other liabilities within our consolidated balance sheets. At December 25, 2021, the current portion of contract liabilities of $ 89 million was reported in accrued expenses: Other, and $ 10 million related to non-current contract liabilities was reported in other liabilities. During the year ended December 31, 2022, we recognized substantially all of the current contract liability amounts that were previously deferred at December 25, 2021. At December 31, 2022, the current and non-current portion of contract liabilities were $ 86 million and $ 8 million, respectively.
Inventories and Reserves	Inventories and Reserves Inventories consist primarily of finished goods and are valued at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method for merchandise or actual cost for large equipment and high tech equipment. In accordance with our policy for inventory valuation, we consider many factors including the condition and salability of the inventory, historical sales, forecasted sales and market and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect the value of inventory.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is computed primarily under the straight-line method Amortization of leasehold improvements is computed using the straight-line method over the lesser of the useful life of the assets or the lease term. Capitalized Software Development Costs Capitalized internal-use software costs consist of costs to purchase and develop software. For software to be used solely to meet internal needs and cloud-based applications used to deliver our services, we capitalize costs incurred during the application development stage and include such costs within property and equipment, net within our consolidated balance sheets. For software to be sold, leased, or marketed to external users, we capitalize software development costs when technological feasibility is reached and include such costs in Investments and other within our consolidated balance sheets.
Leases	Leases We determine if an arrangement contains a lease at inception. An arrangement contains a lease if it implicitly or explicitly identifies an asset to be used and conveys the right to control the use of the identified asset in exchange for consideration. As a lessee, we include operating leases in operating lease right-of-use (“ROU”) assets, operating lease liabilities, and non-current operating lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, current maturities of long-term debt, and long-term debt in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized upon commencement of the lease based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate based on the estimated rate of interest for fully collateralized and fully amortizing borrowings over a similar term of the lease payments at commencement date to determine the present value of lease payments. When readily determinable, we use the implicit rate. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Expenses associated with operating leases and finance leases are included in “selling, general and administrative” and “interest expense”, respectively within our consolidated statement of income. Short-term leases with a term of 12 months or less are not capitalized. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, such short-term lease expense was $ 7 million, $ 4 million, and $ 2 million, respectively. We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component, except non-lease components for leases of vehicles, which are accounted for separately. When a vehicle lease contains both lease and non-lease components, we allocate the transaction price based on the relative standalone selling price.
Goodwill	Goodwill Goodwill represents the excess of the purchase price over the estimated fair value of the net assets acquired, including the amount assigned to identifiable intangible assets. Goodwill is subject to impairment analysis annually or more frequently if needed. Such impairment analyses for goodwill requires a comparison of the fair value to the carrying value of reporting units. We regard our reporting units to be our operating segments: global dental; global medical; and technology and value-added services. Goodwill was allocated to such reporting units, for the purposes of preparing our impairment analyses, based on a specific identification basis. For the years ended December 31, 2022 and December 25, 2021, we tested goodwill for impairment, on the first day of the fourth quarter, using a quantitative analysis comparing the carrying value of our reporting units, including goodwill, to the estimated fair value of our reporting units using a discounted cash flow methodology. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired. Conversely, impairment loss would be equivalent to the excess of a reporting unit’s carrying value over its fair value limited to the total amount of goodwill allocated to that reporting unit. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities that are considered shared services to the reporting units, and ultimately the determination of the fair value of each reporting unit. The fair value of each reporting unit is calculated by applying the discounted cash flow methodology and confirming with a market approach. There are inherent uncertainties related to fair value models, the inputs and our judgments in applying them to this analysis. The most significant inputs include estimation of future cash flows based on budget expectations, and determination of comparable companies to develop a weighted average cost of capital for each reporting unit. For the year ended December 31, 2022, we recorded a $ 20 million impairment of goodwill relating to the disposal of an unprofitable business whose estimated fair value was lower than its carrying value. The disposal of this business is part of our restructuring initiative as more fully discussed in For the year ended December 25, 2021, the results of our goodwill impairment analysis did no t result in any impairments.
Intangible Assets	Intangible Assets Intangible assets, other than goodwill, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows to be derived from such assets. Definite-lived intangible assets primarily consist of non-compete agreements, trademarks, trade names, customer lists, customer relationships and product development. For long-lived assets used in operations, impairment losses are only recorded if the asset’s carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. We measure the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value. During the years ended December 31, 2022, December 25, 2021 and December 26, 2020, we recorded total impairment charges on intangible assets of $ 34 million, $ 1 million and $ 20 million, respectively, as more fully discussed in
Income Taxes	Income Taxes We account for income taxes under an asset and liability approach that requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in tax laws or rates. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. We file a consolidated U.S. federal income tax return with our 80% or greater owned U.S. subsidiaries On December 22, 2017, the U.S. government passed the Tax Act, which requires U.S. companies to pay a mandatory one-time transition tax on historical offshore earnings that have not been repatriated to the U.S. The transition tax is payable over eight years. Within our consolidated balance sheets, transition tax of $ 19 million and $ 14 million were included in “accrued taxes” for 2022 and 2021, respectively, and $ 23 million and $ 42 million were included in “other liabilities” for 2022 and 2021, respectively.
Redeemable Noncontrolling Interests	Redeemable Noncontrolling Interests Some minority stockholders in certain of our consolidated subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Their interests in these subsidiaries are classified outside permanent equity on our consolidated balance sheets and are carried at the estimated redemption amounts. The redemption amounts have been estimated based on expected future earnings and cash flow and, if such earnings and cash flow are not achieved, the value of the redeemable noncontrolling interests might be impacted. Changes in the estimated redemption amounts of the noncontrolling interests subject to put options are reflected at each reporting period with a corresponding adjustment to Additional paid-in capital. Future reductions in the carrying amounts are subject to a “floor” amount that is equal to the fair value of the redeemable noncontrolling interests at the time they were originally recorded. The recorded value of the redeemable noncontrolling interests cannot go below the floor level. Adjustments to the carrying amount of noncontrolling interests to reflect a fair value redemption feature do not impact the calculation of earnings per share. Our net income is reduced by the portion of the subsidiaries’ net income that is attributable to redeemable noncontrolling interests. Noncontrolling Interests Non-controlling interest represents the ownership interests of certain minority owners of our consolidated subsidiaries. Our net income is reduced by the portion of the subsidiaries net income that is attributable to noncontrolling interests.
Comprehensive Income	Comprehensive Income Comprehensive income includes certain gains and losses that, under accounting principles generally accepted in the United States, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. Our comprehensive income is primarily comprised of net income, foreign currency translation gain (loss), unrealized gain (loss) from foreign currency hedging activities and pension adjustment gain.
Risk Management and Derivative Financial Instruments	Risk Management and Derivative Financial Instruments We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our objective is to manage the impact that foreign currency exchange rate fluctuations could have on recognized asset and liability fair values, earnings and cash flows, as well as our net investments in foreign subsidiaries. Our risk management policy requires that derivative contracts used as hedges be effective at reducing the risks associated with the exposure being hedged and be designated as a hedge at the inception of the contract. We do not enter into derivative instruments for speculative purposes. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers and foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. Foreign currency forward agreements related to forecasted inventory purchase commitments with foreign suppliers and foreign currency swaps related to foreign currency denominated debt are designated as cash flow hedges. For derivatives that are designated and qualify as cash flow hedges, the changes in the fair value of the derivative is recorded as a component of Accumulated other comprehensive income in stockholders’ equity and subsequently reclassified into earnings in the period(s) during which the hedged transaction affects earnings. We classify the cash flows related to our hedging activities in the same category on our consolidated statements of cash flows as the cash flows related to the hedged item. Foreign currency forward contracts related to our euro-denominated foreign operations are designated as net investment hedges. For derivatives that are designated and qualify as net investment hedges, the changes in the fair value of the derivative is recorded in the foreign currency translation gain (loss) component of Accumulated other comprehensive income in stockholders’ equity until the net investment is sold or substantially liquidated. Our foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes. For agreements not designated as hedges, changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded in other, net, within our consolidated statements of income. Total return swaps are entered into for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. This swap is expected to be renewed on an annual basis and is recorded in selling, general, and administrative expenses within our consolidated statements of income.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions The financial position and results of operations of our foreign subsidiaries are determined using local currency as the functional currency. Assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each year-end. Income statement accounts are translated at the average rate of exchange prevailing during the year. Translation adjustments arising from the use of differing exchange rates from period to period are included in Accumulated other comprehensive income in stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in earnings.
Accounting Pronouncements Adopted	Accounting Pronouncements Adopted On December 26, 2021 we adopted Accounting Standards Update (“ASU”) No. 2021 – 08, “Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (Subtopic 805). ASU 2021 – 08 requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASU No. 2014 - 09, “Revenue from Contracts with Customers” (Topic 606). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. Our adoption of ASU 2021 - 08 did not have a material impact on our consolidated financial statements. On December 27, 2020 we adopted ASU No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements. Recently Issued Accounting Standards In September 2022, the FASB issued ASU No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405- 50): Disclosure of Supplier Finance Program Obligations” which will increase transparency of supplier finance programs by requiring entities that use such programs in connection with the purchase of goods and services to disclose certain qualitative and quantitative information about such programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for amended rollforward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements. In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope (“ASU 2021-01”). ASU 2021-01 provides temporary optional expedients and exceptions to certain guidance in U.S. GAAP to ease the financial reporting burdens related to the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate. The guidance became effective upon issuance, on January 7, 2021, and can be applied through December 31, 2022. In December 2022, the FASB issued ASU No. 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” which extends the period of application of temporary optional expedients from December 21, 2022 to December 31, 2024. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements.

Net Sales from Contracts with Customers (Tables)	12 Months Ended
Net Sales from Contracts with Customers (Tables)	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Disaggregation of Revenue	Year Ended December 31, 2022 North America International Global Net Sales: Health care distribution Dental $ 4,628 $ 2,845 $ 7,473 Medical 4,375 76 4,451 Total health care distribution 9,003 2,921 11,924 Technology and value-added services 633 90 723 Net sales $ 9,636 $ 3,011 $ 12,647 Year Ended December 25, 2021 North America International Global Net Sales: Health care distribution Dental $ 4,506 $ 3,038 $ 7,544 Medical 4,107 103 4,210 Total health care distribution 8,613 3,141 11,754 Technology and value-added services 560 87 647 Net sales $ 9,173 $ 3,228 $ 12,401 Year Ended December 26, 2020 North America International Global Net Sales: Health care distribution Dental $ 3,472 $ 2,441 $ 5,913 Medical 3,515 102 3,617 Total health care distribution 6,987 2,543 9,530 Technology and value-added services 447 67 514 Total excluding Corporate TSA net sales (1) 7,434 2,610 10,044 Corporate TSA net sales (1) - 75 75 Net sales $ 7,434 $ 2,685 $ 10,119 (1) Corporate TSA net sales represents sales of certain animal health products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020.

Segment and Geographic Data (Tables)	12 Months Ended
Segment and Geographic Data (Tables)	Dec. 31, 2022
Segment and Geographic Data [Abstract]
Business Segment Information	Years Ended December 31, December 25, December 26, 2022 2021 2020 Net Sales: Health care distribution (1) Dental $ 7,473 $ 7,544 $ 5,913 Medical 4,451 4,210 3,617 Total health care distribution 11,924 11,754 9,530 Technology and value-added services (2) 723 647 514 Total excluding Corporate TSA net sales 12,647 12,401 10,044 Corporate TSA net sales (3) - - 75 Total $ 12,647 $ 12,401 $ 10,119 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. (3) Corporate TSA net sales represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. Years ended December 31, December 25, December 26, 2022 2021 2020 Operating Income: Health care distribution $ 619 $ 727 $ 436 Technology and value-added services 128 125 99 Total $ 747 $ 852 $ 535 Income from continuing operations before taxes and equity in earnings of affiliates: Health care distribution $ 592 $ 706 $ 400 Technology and value-added services 129 125 100 Total $ 721 $ 831 $ 500 Depreciation and Amortization: Health care distribution $ 160 $ 157 $ 143 Technology and value-added services 52 53 43 Total $ 212 $ 210 $ 186 Interest Income: Health care distribution $ 16 $ 7 $ 10 Technology and value-added services 1 - - Total $ 17 $ 7 $ 10 Interest Expense: Health care distribution $ 44 $ 28 $ 41 Total $ 44 $ 28 $ 41 Income Tax Expense: Health care distribution $ 141 $ 168 $ 71 Technology and value-added services 29 30 24 Total $ 170 $ 198 $ 95 Purchases of Fixed Assets: Health care distribution $ 86 $ 74 $ 44 Technology and value-added services 10 5 5 Total $ 96 $ 79 $ 49 As of December 31, December 25, December 26, 2022 2021 2020 Total Assets: Health care distribution $ 7,287 $ 7,157 $ 6,503 Technology and value-added services 1,320 1,324 1,270 Total $ 8,607 $ 8,481 $ 7,773
Operations by Geographic Area	2022 2021 2020 Net Sales Long-Lived Assets Net Sales Long-Lived Assets Net Sales Long-Lived Assets United States $ 9,190 $ 2,891 $ 8,722 $ 2,981 $ 7,090 $ 2,363 Other 3,457 1,256 3,679 1,232 3,029 1,252 Consolidated total $ 12,647 $ 4,147 $ 12,401 $ 4,213 $ 10,119 $ 3,615

Business Acquisitions and Divestitures (Tables)	12 Months Ended
Business Acquisitions and Divestitures (Tables)	Dec. 31, 2022
Business Acquisitions and Divestitures [Abstract]
Acquisition Consideration	2022 Acquisition consideration: Cash $ 158 Deferred consideration 2 Fair value of previously held equity method investment 16 Redeemable noncontrolling interests 17 Total consideration $ 193 Identifiable assets acquired and liabilities assumed: Current assets $ 41 Intangible assets 96 Other noncurrent assets 13 Current liabilities (29) Deferred income taxes (6) Other noncurrent liabilities (8) Total identifiable net assets 107 Goodwill 86 Total net assets acquired $ 193 2021 Acquisition consideration: Cash $ 579 Deferred consideration 11 Estimated fair value of contingent consideration receivable (5) Fair value of previously held equity method investment 8 Redeemable noncontrolling interests 181 Total consideration $ 774 Identifiable assets acquired and liabilities assumed: Current assets $ 195 Intangible assets 317 Other noncurrent assets 51 Current liabilities (93) Deferred income taxes (26) Other noncurrent liabilities (46) Total identifiable net assets 398 Goodwill 376 Total net assets acquired $ 774 2020 Acquisition consideration: Cash $ 52 Deferred consideration 6 Fair value of previously held equity method investment 9 Redeemable noncontrolling interests 26 Total consideration $ 93 Identifiable assets acquired and liabilities assumed: Current assets $ 36 Intangible assets 38 Other noncurrent assets 22 Current liabilities (21) Deferred income taxes (4) Other noncurrent liabilities (1) Total identifiable net assets 70 Goodwill 23 Total net assets acquired $ 93
Intangible Assets	Estimated Useful Lives 2022 (in years) Customer relationships and lists 81 8 - 12 Trademark / Tradename 9 5 Non-compete agreements 3 2 - 5 Other 3 10 $ 96 Estimated Useful Lives 2021 (in years) Customer relationships and lists $ 220 5 - 12 Trademark / Tradename 58 5 - 12 Product development 19 5 - 10 Non-compete agreements 5 3 - 5 Other 15 18 $ 317 Estimated Useful Lives 2020 (in years) Customer relationships and lists $ 23 10 - 12 Product development 9 7 - 10 Trademark / Tradename 4 5 Non-compete agreements 2 5 $ 38

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and equipment, including related estimated useful lives	December 31, December 25, 2022 2021 Land $ 20 $ 21 Buildings and permanent improvements 135 140 Leasehold improvements 94 98 Machinery and warehouse equipment 169 153 Furniture, fixtures and other 127 119 Computer equipment and software 411 385 956 916 Less accumulated depreciation (573) (550) Property and equipment, net $ 383 $ 366 Estimated Useful Lives (in years) Buildings and permanent improvements 40 Machinery and warehouse equipment 5 - 10 Furniture, fixtures and other 3 - 10 Computer equipment and software 3 - 10

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2022
Leases [Abstract]
Components of Lease Expense, Supplemental Cash Flow and Supplemental Balance Sheet Information	Years Ended December 31, December 25, December 26, 2022 2021 2020 Operating lease cost: (1) (2) $ 150 $ 103 $ 87 Finance lease cost: Amortization of right-of-use assets 3 3 2 Total finance lease cost $ 3 $ 3 $ 2 (1) Includes variable lease expenses. (2) Operating lease cost for the years ended December 31, 2022, December 25, 2021, and December 26, 2020, include accelerated amortization of right-of-use assets of $ 42 million, $ 0 million and $ 0 million, respectively, related to facility leases recorded in “Restructuring and integration costs” within our consolidated statements of income. Years Ended December 31, December 25, 2022 2021 Operating Leases: Operating lease right-of-use assets $ 284 $ 325 Current operating lease liabilities 73 76 Non-current operating lease liabilities 275 268 Total operating lease liabilities $ 348 $ 344 Finance Leases: Property and equipment, at cost $ 16 $ 13 Accumulated depreciation (6) (5) Property and equipment, net of accumulated depreciation $ 10 $ 8 Current maturities of long-term debt $ 4 $ 3 Long-term debt 6 4 Total finance lease liabilities $ 10 $ 7 Weighted Average Remaining Lease Term in Years: Operating leases 6.7 7.3 Finance leases 3.1 3.6 Weighted Average Discount Rate: Operating leases 2.8 % 2.4 % Finance leases 3.3 % 1.7 % Years Ended December 31, December 25, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 87 85 Financing cash flows for finance leases 3 3 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 88 121 Finance leases 6 4
Maturities of Finance and Operating Lease Liabilities	December 31, 2022 Operating Finance Leases Leases 2023 $ 82 $ 5 2024 66 3 2025 56 1 2026 46 1 2027 33 - Thereafter 98 1 Total future lease payments 381 11 Less imputed interest (33) (1) Total $ 348 $ 10

Goodwill and Other Intangibles, Net (Tables)	12 Months Ended
Goodwill and Other Intangibles, Net (Tables)	Dec. 31, 2022
Goodwill and Other Intangibles, Net [Abstract]
Changes in the Carrying Amount of Goodwill	Health Care Distribution Technology and Value-Added Services Total Balance as of December 26, 2020 $ 1,501 $ 1,003 $ 2,504 Adjustments to goodwill: Acquisitions 359 24 383 Foreign currency translation (29) (4) (33) Balance as of December 25, 2021 1,831 1,023 2,854 Adjustments to goodwill: Acquisitions 86 (1) 85 Impairment (20) - (20) Foreign currency translation (22) (4) (26) Balance as of December 31, 2022 $ 1,875 $ 1,018 $ 2,893
Other Intangible Assets - Finite-Lived	December 31, 2022 December 25, 2021 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Customer lists and relationships $ 826 $ (387) $ 439 $ 853 $ (353) $ 500 Trademarks / trade names - definite lived 125 (51) 74 129 (44) 85 Product Development 90 (56) 34 114 (70) 44 Non-compete agreements 25 (6) 19 25 (6) 19 Other 31 (10) 21 28 (8) 20 Total $ 1,097 $ (510) $ 587 $ 1,149 $ (481) $ 668

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Investments and Other (Tables)	12 Months Ended
Investments and Other (Tables)	Dec. 31, 2022
Investments And Other [Abstract]
Investments and Other	December 31, December 25, 2022 2021 Investment in unconsolidated affiliates $ 161 $ 168 Non-current deferred foreign, state and local income taxes 88 35 Notes receivable (1) 28 36 Capitalized costs for software to be sold, leased or marketed to external users 79 65 Security deposits 3 2 Acquisition-related indemnification 59 66 Non-current pension assets 8 - Other long-term assets 46 52 Total $ 472 $ 424 (1) Long-term notes receivable carry interest rates ranging from 3.0 % to 7.5 % and are due in varying installments through May 11, 2028 .

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2022
Fair Value Measurements [Abstract]
Fair value - assets and liabilities measured and recognized on a recurring basis	December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return swaps - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576 December 25, 2021 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 8 $ - $ 8 Derivative contracts undesignated - 1 - 1 Total return swap - 1 - 1 Total assets $ - $ 10 $ - $ 10 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 3 $ - $ 3 Redeemable noncontrolling interests $ - $ - $ 613 $ 613

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2022
Debt [Abstract]
Bank Credit Lines	December 31, December 25, 2022 2021 Revolving credit agreement $ - $ - Other short-term bank credit lines 103 51 Total $ 103 $ 51
Schedule of Long-Term Debt	December 31, December 25, 2022 2021 Private placement facilities $ 699 $ 706 U.S. trade accounts receivable securitization 330 105 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 3.50 % at December 31, 2022 and ranging from 2.62 % to 4.27 % at December 25, 2021 7 4 Finance lease obligations 10 7 Total 1,046 822 Less current maturities (6) (11) Total long-term debt $ 1,040 $ 811
Private Placement Facilities	Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 Less: Deferred debt issuance costs (1) Total $ 699
Schedule of Long-Term Debt Maturities	2023 $ 6 2024 109 2025 331 2026 - 2027 100 Thereafter 500 Total $ 1,046

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2022
Income Taxes [Abstract]
Income Before Taxes, Equity in Earnings of Affiliates and Loss on Sale of Equity Investment	Years ended December 31, December 25, December 26, 2022 2021 2020 Domestic $ 506 $ 593 $ 431 Foreign 215 238 69 Total $ 721 $ 831 $ 500
Provision for Income Taxes Attributable to Continuing Operations	The provisions for income taxes were as follows: Years ended December 31, December 25, December 26, 2022 2021 2020 Current income tax expense: U.S. Federal $ 150 $ 129 $ 83 State and local 49 37 24 Foreign 44 43 41 Total current 243 209 148 Deferred income tax expense (benefit): U.S. Federal (48) (12) (18) State and local (13) (3) (5) Foreign (12) 4 (30) Total deferred (73) (11) (53) Total provision $ 170 $ 198 $ 95
Tax Effects of Temporary Differences to Deferred Income Tax Asset (Liability)	The tax effects of temporary differences that give rise to our deferred income tax asset (liability) were as follows: Years Ended December 31, December 25, 2022 2021 Deferred income tax asset: Net operating losses and other carryforwards $ 64 $ 55 Inventory, premium coupon redemptions and accounts receivable valuation allowances 57 46 Stock-based compensation 11 13 Uniform capitalization adjustment to inventories 11 10 Operating lease liability 77 79 Other asset 48 41 Total deferred income tax asset 268 244 Valuation allowance for deferred tax assets (1) (36) (36) Net deferred income tax asset 232 208 Deferred income tax liability Intangibles amortization (112) (134) Operating lease right-of-use asset (61) (74) Property and equipment (7) (7) Total deferred tax liability (180) (215) Net deferred income tax asset (liability) $ 52 $ (7) (1) Primarily relates to operating losses, the benefits of which are uncertain. Any future reductions of such valuation allowances will be reflected as a reduction of income tax expense.
Reconciliation of Income Tax Provision at Federal Statutory Rate to Total Income Tax Provision	Years ended December 31, December 25, December 26, 2022 2021 2020 Income tax provision at federal statutory rate $ 151 $ 175 $ 105 State income tax provision, net of federal income tax effect 20 21 13 Foreign income tax provision 4 6 - Pass-through noncontrolling interest (4) (4) (3) Valuation allowance (2) (6) 1 Unrecognized tax benefits and audit settlements 11 7 (18) Interest expense related to loans (12) (11) (11) Tax benefit related to legal entity reorganization outside the U.S. - - (6) Other 2 10 14 Total income tax provision $ 170 $ 198 $ 95
Reconciliation of Unrecognized Tax Benefits Excluding the Effect of Deferred Taxes	December 31, December 25, December 26, 2022 2021 2020 Balance, beginning of period $ 71 $ 70 $ 91 Additions based on current year tax positions 14 3 5 Additions based on prior year tax positions 8 11 8 Reductions based on prior year tax positions - (1) (1) Reductions resulting from settlements with taxing authorities (1) (9) (19) Reductions resulting from lapse in statutes of limitations (10) (3) (14) Balance, end of period $ 82 $ 71 $ 70

Plans of Restructuring and Integration Costs (Tables)	12 Months Ended
Plans of Restructuring and Integration Costs (Tables)	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost	Year Ended December 31, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 25 $ - $ 4 $ - $ 29 Impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets 47 - - - 47 Exit and other related costs 3 - - - 3 Loss on disposal of a business 49 - 49 Integration employee-related and other costs - 3 - - 3 Total restructuring and integration costs $ 124 $ 3 $ 4 $ - $ 131 Year Ended December 25, 2021 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 6 $ - $ 2 $ - $ 8 Total restructuring and integration costs $ 6 $ - $ 2 $ - $ 8 Year Ended December 26, 2020 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 25 $ - $ 1 $ - $ 26 Impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets 4 - - - 4 Exit and other related costs 2 - - - 2 Total restructuring and integration costs $ 31 $ - $ 1 $ - $ 32
Schedule of Restructuring Reserve by Segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 25, 2021 $ 3 $ 1 $ 4 Restructuring charges 124 4 128 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (47) - (47) Non-cash impairment on disposal of a business (46) - (46) Cash payments and other adjustments (13) (2) (15) Balance, December 31, 2022 $ 21 $ 3 $ 24

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Purchase commitments	2023 $ 5 2024 4 2025 4 2026 4 2027 4 Thereafter - Total minimum inventory purchase commitment payments $ 21

Stock Based Compensation (Tables)	12 Months Ended
Stock Based Compensation (Tables)	Dec. 31, 2022
Stock Based Compensation [Abstract]
Valuation Model	2022 Expected dividend yield 0.00 % Expected stock price volatility 27.80 % Risk-free interest rate 3.62 % Expected life of options (years) 6.00
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Remaining Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life in Years Value Outstanding at beginning of year 767,717 $ 63.24 Granted 420,075 85.81 Exercised (36,150) 62.92 Forfeited (34,068) 74.84 Outstanding at end of year 1,117,574 $ 71.38 8.5 $ 12 Options exercisable at end of year 220,688 $ 63.35
Intrinsic Values	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 885,428 $ 73.50 8.7 $ 8
Status of Non-Vested Restricted Shares/Units	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,945,862 $ 58.79 674,753 $ 59.63 Granted 471,840 85.49 267,865 82.35 Vested (566,887) 55.46 (396,220) 59.21 Forfeited (94,771) 67.87 (25,482) 67.65 Outstanding at end of period 1,756,044 $ 66.59 $ 79.87 520,916 $ 60.23 $ 79.87

Employee Benefit Plans (Tables)	12 Months Ended
Employee Benefit Plans (Tables)	Dec. 31, 2022
Employee Benefit Plans [Abstract]
Obligation and Funded Status	Years Ended December 31, December 25, 2022 2021 Obligation and funded status: Change in benefit obligation Projected benefit obligation, beginning of period $ 128 $ 130 Service costs 3 4 Interest cost 1 - Past service cost - 5 Actuarial loss (19) (5) Benefits paid (1) (1) - Participant contributions 1 1 Settlements (1) (2) Effect of foreign currency translation (4) (5) Projected benefit obligation, end of period $ 108 $ 128 Change in plan assets Fair value of plan assets at beginning of period $ 75 $ 65 Actual return on plan assets (3) 5 Employer contributions 2 2 Plan participant contributions 1 1 Expected return on plan assets 1 4 Benefit received (1) - 2 Settlements (1) (3) Effect of foreign currency translation (2) (1) Fair value of plan assets at end of period $ 73 $ 75 Unfunded status at end of period $ 35 $ 53 Includes regular benefit payments and amounts transferred in by new participants.
Balance Sheet	Years Ended December 31, December 25, 2022 2021 Non-current assets $ 25 $ 22 Current liabilities (1) (1) Non-current liabilities (59) (74) Accumulated other comprehensive loss, pre-tax 4 21
Net Periodic Pension Cost	Years Ended December 31, December 25, December 26, 2022 2021 2020 Service cost $ 3 $ 4 $ 3 Interest cost 1 - - Expected return on plan assets (1) (1) - Employee contributions - - - Amortization of prior service credit 1 1 1 Recognized net actuarial loss - - - Settlements - - - Net periodic pension cost $ 4 $ 4 $ 4
Assumptions	Years Ended December 31, December 25, Pension Benefit Obligation 2022 2021 Weighted average discount rate 1.67 % 0.87 % Years Ended December 31, December 25, December 26, Net Periodic Pension Cost 2022 2021 2020 Discount rate-pension benefit 1.25 % 0.56 % 0.51 % Expected return on plan assets 0.81 % 0.71 % 0.87 % Rate of compensation increase 1.68 % 1.95 % 1.97 % Pension increase rate 0.61 % 0.72 % 0.67 %
Estimated Payments	Year 2023 $ 6 2024 6 2025 5 2026 5 2027 7 2028 to 2032 38 Total $ 67

Redeemable Noncontrolling Interests (Tables)	12 Months Ended
Redeemable Noncontrolling Interests (Tables)	Dec. 31, 2022
Redeemable Noncontrolling Interests [Abstract]
Change in Fair Value of Redeemable Noncontrolling Interests	December 31, December 25, December 26, 2022 2021 2020 Balance, beginning of period $ 613 $ 328 $ 287 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (31) (60) (17) Increase in redeemable noncontrolling interests due to business acquisitions 4 189 28 Net income attributable to redeemable noncontrolling interests 21 23 14 Dividends declared (21) (21) (13) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (6) (6) (4) Change in fair value of redeemable securities (4) 160 33 Balance, end of period $ 576 $ 613 $ 328

Comprehensive Income (Tables)	12 Months Ended
Comprehensive Income (Tables)	Dec. 31, 2022
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income and Comprehensive Income Components	December 31, December 25, December 26, 2022 2021 2020 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (37) $ (31) $ (25) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ - $ - Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (236) $ (155) $ (77) Unrealized gain (loss) from foreign currency hedging activities 5 (2) (11) Pension adjustment loss (2) (14) (20) Accumulated other comprehensive loss $ (233) $ (171) $ (108) Total Accumulated other comprehensive loss $ (271) $ (202) $ (133)
Components of comprehensive income, net of applicable taxes	December 31, December 25, December 26, 2022 2021 2020 Net income $ 566 $ 660 $ 420 Foreign currency translation gain (loss) (88) (84) 63 Tax effect - - - Foreign currency translation gain (loss) (88) (84) 63 Unrealized gain (loss) from foreign currency hedging activities 10 12 (10) Tax effect (3) (3) 3 Unrealized gain (loss) from foreign currency hedging activities 7 9 (7) Pension adjustment gain 16 8 - Tax effect (4) (2) - Pension adjustment gain 12 6 - Comprehensive income $ 497 $ 591 $ 476
Total Comprehensive Income	December 31, December 25, December 26, 2022 2021 2020 Comprehensive income attributable to Henry Schein, Inc. $ 476 $ 568 $ 463 Comprehensive income attributable to noncontrolling interests 6 6 3 Comprehensive income attributable to Redeemable noncontrolling interests 15 17 10 Comprehensive income $ 497 $ 591 $ 476

Discontinued Operations (Tables)	12 Months Ended
Discontinued Operations (Tables)	Dec. 31, 2022
Discontinued Operations [Abstract]
Summarized Financial Information for Discontinued Operations	Year Ended December 26, 2020 Selling, general and administrative 2 Operating loss (2) Income tax benefit (3) Income from discontinued operations 1 Net income from discontinued operations attributable to Henry Schein, Inc. 1

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Earnings Per Share (Tables)	12 Months Ended
Earnings Per Share (Tables)	Dec. 31, 2022
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Years Ended December 31, December 25, December 26, 2022 2021 2020 Basic 136,064,221 140,090,889 142,504,193 Effect of dilutive securities: Stock options and restricted stock units 1,691,449 1,681,892 899,489 Diluted 137,755,670 141,772,781 143,403,682
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Years Ended December 31, December 25, December 26, 2022 2021 2020 Stock options 342,716 611,869 - Restricted stock units 19,466 1,048 2,398 Total anti-dilutive securities excluded from EPS computation 362,182 612,917 2,398

Supplemental Cash Flow Information (Tables)	12 Months Ended
Supplemental Cash Flow Information (Tables)	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Cash Paid for Interest and Income Taxes	Years ended December 31, December 25, December 26, 2022 2021 2020 Interest $ 47 $ 29 $ 43 Income taxes 265 242 207

Basis of Presentation and Significant Accounting Policies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Fiscal year duration	371 days	364 days	364 days
Accrued warranty costs	$ 8,000,000	$ 8,000,000
Distribution network costs	103,000,000	89,000,000	$ 72,000,000
Costs of goods sold	8,816,000,000	8,727,000,000	7,303,000,000
Advertising and promotional costs	47,000,000	48,000,000	32,000,000
Outstanding checks in excess of funds on deposit classified as accounts payable	54,000,000	2,000,000
Contract liabilities, current	86,000,000	89,000,000
Contract liabilities, noncurrent	$ 8,000,000	10,000,000
Lease option to extend	Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.
Short-term lease expense	$ 7,000,000	4,000,000	2,000,000
Allowance for doubtful accounts	65,000,000	67,000,000	88,000,000
Additions to allowance for doubtful accounts	8,000,000	0	36,000,000
Deductions to allowance for doubtful accounts	10,000,000	21,000,000	8,000,000
Goodwill impairment	20,000,000	0
Impairment charge on intangible assets	$ 34,000,000	1,000,000	20,000,000
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Fiscal year duration	364 days
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Fiscal year duration	371 days
Shipping and Handling [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Costs of goods sold	$ 96,000,000	97,000,000	$ 79,000,000
Variable Interest Entity, Primary Beneficiary [Member] \| Recourse [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Liabilities of VIE	255,000,000	105,000,000
Variable Interest Entity, Primary Beneficiary [Member] \| Asset Pledged As Collateral [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Pledged assets	$ 327,000,000	$ 138,000,000

Net Sales from Contracts with Customers (Disaggregation of Revenue) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Disaggregation of Revenue [Abstract]
Net sales	$ 12,647	$ 12,401	$ 10,119
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	9,636	9,173	7,434
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	3,011	3,228	2,685
Total excluding Corporate TSA revenues
Disaggregation of Revenue [Abstract]
Net sales	12,647	12,401	10,044
Total excluding Corporate TSA revenues \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales			7,434
Total excluding Corporate TSA revenues \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales			2,610
Healthcare Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	11,924	11,754	9,530
Healthcare Distribution [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	9,003	8,613	6,987
Healthcare Distribution [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,921	3,141	2,543
Healthcare Distribution [Member] \| Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	7,473	7,544	5,913
Healthcare Distribution [Member] \| Dental [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	4,628	4,506	3,472
Healthcare Distribution [Member] \| Dental [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,845	3,038	2,441
Healthcare Distribution [Member] \| Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	4,451	4,210	3,617
Healthcare Distribution [Member] \| Medical [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	4,375	4,107	3,515
Healthcare Distribution [Member] \| Medical [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	76	103	102
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	723	647	514
Technology and Value-Added Services [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	633	560	447
Technology and Value-Added Services [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	90	87	67
Corporate TSA [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 0	$ 0	75
Corporate TSA [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales			0
Corporate TSA [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales			$ 75

Segment and Geographic Data (Narrative) (Details)	12 Months Ended
Segment and Geographic Data (Narrative) (Details)	Dec. 31, 2022 number countries
Segment Reporting Information [Line Items]
Number of reportable segments \| number	2
Number of countries served globally \| countries	32
Minimum [Member] \| United States [Member] \| Geographic Concentration Risk [Member] \| Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Concentration risk percentage (as a percent)	10.00%

Segment and Geographic Data (Business Segment Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Segment Reporting Information [Line Items]
Net sales	$ 12,647	$ 12,401	$ 10,119
Operating income	747	852	535
Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment	721	831	500
Depreciation and amortization	212	210	186
Interest income	17	7	10
Interest expense	44	28	41
Income taxes	170	198	95
Purchases of fixed assets	96	79	49
Total assets	8,607	8,481	7,773
Total excluding Corporate TSA revenues
Segment Reporting Information [Line Items]
Net sales	12,647	12,401	10,044
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	11,924	11,754	9,530
Operating income	619	727	436
Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment	592	706	400
Depreciation and amortization	160	157	143
Interest income	16	7	10
Interest expense	44	28	41
Income taxes	141	168	71
Purchases of fixed assets	86	74	44
Total assets	7,287	7,157	6,503
Health Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales	7,473	7,544	5,913
Health Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales	4,451	4,210	3,617
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	723	647	514
Operating income	128	125	99
Income from before taxes, equity in earnings of affiliates and loss on sale of equity investment	129	125	100
Depreciation and amortization	52	53	43
Interest income	1	0	0
Interest expense	0	0	0
Income taxes	29	30	24
Purchases of fixed assets	10	5	5
Total assets	1,320	1,324	1,270
Corporate TSA [Member]
Segment Reporting Information [Line Items]
Net sales	$ 0	$ 0	$ 75

Segment and Geographic Data (Operations by Geographic Area) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 12,647	$ 12,401	$ 10,119
Long-Lived Assets	4,147	4,213	3,615
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	9,190	8,722	7,090
Long-Lived Assets	$ 2,891	2,981	2,363
United States [Member] \| Geographic Concentration Risk [Member] \| Sales revenue, net [Member] \| Minimum [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage (as a percent)	10.00%
Locations other than the United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 3,457	3,679	3,029
Long-Lived Assets	$ 1,256	$ 1,232	$ 1,252

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Business Acquisitions and Divestitures (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Sep. 25, 2021	Dec. 26, 2020	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Business Acquisition [Line Items]
Business acquisition allocated, goodwill		$ 2,504	$ 2,893	$ 2,854	$ 2,504
Income taxes			170	198	95
Equity in earnings of affiliates			15	20	12
Net sales			12,647	12,401	10,119
Contingent consideration receivable				5
Increase in contingent consideration receivable			5
Business Acquisition, Transaction Costs		6	9	7	6
Proceeds from sale of equity investment			0	10	14
After-tax gain on sale of equity investments			0	7	2
Hu-Friedy Mfg. Co., LLC [Member]
Business Acquisition [Line Items]
Proceeds from sale of equity investment	$ 10	2
After-tax gain on sale of equity investments	$ 7	2
Technology and Value-Added Services [Member]
Business Acquisition [Line Items]
Business acquisition allocated, goodwill		1,003	1,018	1,023	1,003
Income taxes			29	30	24
Net sales			723	647	514
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses			158	579	52
Net assets		70	107	398	70
Intangible Assets		38	96	317	38
Business acquisition allocated, goodwill		$ 23	86	376	23
Noncontrolling Interest, Increase from Business Combination			17	181	26
Business Combination Consideration Transferred 1			$ 193	$ 774	$ 93
Series of Individually Immaterial Business Acquisitions [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Acquired equity interest (as a percent)		51.00%	55.00%	51.00%	51.00%
Series of Individually Immaterial Business Acquisitions [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquired equity interest (as a percent)		100.00%	100.00%	100.00%	100.00%

Business Acquisitions and Divestitures (Acquisition Consideration) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Business Acquisition [Line Items]
Goodwill	$ 2,893	$ 2,854	$ 2,504
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Cash	158	579	52
Deferred consideration	2	11	6
Estimated fair value of contingent consideration receivable		(5)
Fair value of previously held equity method investment	16	8	9
Redeemable noncontrolling interests	17	181	26
Total	193	774	93
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets	41	195	36
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	96	317	38
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets	13	51	22
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities	(29)	(93)	(21)
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities	(6)	(26)	(4)
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other	(8)	(46)	(1)
Total	107	398	70
Goodwill	86	376	23
Total	$ 193	$ 774	$ 93

Business Acquisitions and Divestitures (Intangible Assets) (Details) - Series of Individually Immaterial Business Acquisitions [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Business Acquisition [Line Items]
Finitelived Intangible Assets Acquired 1	$ 96	$ 317	$ 38
Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Finitelived Intangible Assets Acquired 1	$ 81	$ 220	$ 23
Customer Relationships and Lists [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life	8 years	5 years	10 years
Customer Relationships and Lists [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life	12 years	12 years	12 years
Trademark And Tradename [Member]
Business Acquisition [Line Items]
Finitelived Intangible Assets Acquired 1	$ 9	$ 58	$ 4
Acquired Finite Lived Intangible Assets Weighted Average Useful Life	5 years		5 years
Trademark And Tradename [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life		5 years
Trademark And Tradename [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life		12 years
Product Development [Member]
Business Acquisition [Line Items]
Finitelived Intangible Assets Acquired 1		$ 19	$ 9
Product Development [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life		5 years	7 years
Product Development [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life		10 years	10 years
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Finitelived Intangible Assets Acquired 1	$ 3	$ 5	$ 2
Acquired Finite Lived Intangible Assets Weighted Average Useful Life			5 years
Noncompete Agreements [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life	2 years	3 years
Noncompete Agreements [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Acquired Finite Lived Intangible Assets Weighted Average Useful Life	5 years	5 years
Other Intangible Assets [Member]
Business Acquisition [Line Items]
Finitelived Intangible Assets Acquired 1	$ 3	$ 15
Acquired Finite Lived Intangible Assets Weighted Average Useful Life	10 years	18 years

Property and Equipment, Net (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 956	$ 956	$ 916
Less accumulated depreciation	(573)	(573)	(550)
Property and equipment related depreciation expense		68	71	$ 64
Restructuring charges	128	128
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20	20	21
Buildings and permanent improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	135	$ 135	140
Property and equipment, average useful life (in years)		40 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	94	$ 94	98
Machinery and warehouse equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	169	$ 169	153
Machinery and warehouse equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)		5 years
Machinery and warehouse equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)		10 years
Furniture, fixtures and other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	127	$ 127	119
Furniture, fixtures and other [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)		3 years
Furniture, fixtures and other [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)		10 years
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 411	$ 411	$ 385
Computer equipment and software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)		3 years
Computer equipment and software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, average useful life (in years)		10 years

Leases (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Leases (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Lessee, Lease, Description [Line Items]
Operating lease assets, Lease not yet commenced	$ 8
Amortization expense including operating lease credits	42	$ 0	$ 0
Impairment of right-of-use asset from operating lease	3	0	$ 4
Current operating lease liabilities	73	76
Non-current operating lease liabilities	275	$ 268
Property Owned By Employees And Shareholders [Member]
Lessee, Lease, Description [Line Items]
Current operating lease liabilities	4
Non-current operating lease liabilities	$ 14
Property Owned By Employees And Shareholders [Member] \| Current Operating Lease Liabilities [Member] \| Related Party Concentration Risk [Member]
Lessee, Lease, Description [Line Items]
Concentration risk percentage (as a percent)	5.00%
Property Owned By Employees And Shareholders [Member] \| Non-Current Operating Lease Liabilities [Member] \| Related Party Concentration Risk [Member]
Lessee, Lease, Description [Line Items]
Concentration risk percentage (as a percent)	5.30%
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Operating lease not yet commenced, term of contract	2 years
Minimum [Member] \| Property Owned By Employees And Shareholders [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	4 months
Maximum [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	19 years
Lease option to extend (in years)	15 years
Operating lease not yet commenced, term of contract	5 years
Maximum [Member] \| Property Owned By Employees And Shareholders [Member]
Lessee, Lease, Description [Line Items]
Remaining lease term	9 years

Leases (Components of Lease Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Leases [Abstract]
Operating lease cost	$ 150	$ 103	$ 87
Finance lease cost:
Amortization of right-of-use assets	3	3	2
Finance lease cost	$ 3	$ 3	$ 2

Leases (Supplemental Balance Sheet Information) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Operating Leases
Operating lease right-of-use assets	$ 284	$ 325
Current operating lease liabilities	73	76
Non-current operating lease liabilities	275	268
Total operating lease liabilities	348	344
Finance leases
Property and equipment, at cost	16	13
Accumulated depreciation	(6)	(5)
Property and equipment, net of accumulated depreciation	10	8
Current maturities of long-term debt	$ 4	$ 3
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Long-term Debt and Capital Lease Obligations, Current	Long-term Debt and Capital Lease Obligations, Current
Long-term debt	$ 6	$ 4
Total finance lease liabilities	$ 10	$ 7
Weighted Average Remaining Lease Term, in years, Operating Lease	6 years 8 months 12 days	7 years 3 months 18 days
Weighted Average Remaining Lease Term, in years, Finance Lease	3 years 1 month 6 days	3 years 7 months 6 days
Weighted Average Discount Rate, Percent, Operating Lease	2.80%	2.40%
Weighted Average Discount Rate, Percent, Finance Lease	3.30%	1.70%

Leases (Supplemental Cash Flow Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$ 87	$ 85
Financing cash flows for finance leases	3	3
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	88	121
Finance leases	$ 6	$ 4

Leases (Maturities of Lease Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Operating Leases
2023	$ 82
2024	66
2025	56
2026	46
2027	33
Thereafter	98
Total future lease payments	381
Less imputed interest	(33)
Total operating lease liabilities	348	$ 344
Finance Leases
2023	5
2024	3
2025	1
2026	1
2027	0
Thereafter	1
Total future lease payments	11
Less imputed interest	(1)
Total finance lease liabilities	$ 10	$ 7

Goodwill and Other Intangibles, Net (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Goodwill and Intangible Assets [Line Items]
Goodwill impairment		$ 20,000,000	$ 0
Amortization of intabgible assets		126,000,000	124,000,000	$ 106,000,000
Impairment charge on intangible assets		34,000,000	1,000,000	20,000,000
Restructuring charges	$ 128,000,000	128,000,000
Amortization expense expected to be recorded 2023	120,000,000	120,000,000
Amortization expense expected to be recorded 2024	96,000,000	96,000,000
Amortization expense expected to be recorded 2025	84,000,000	84,000,000
Amortization expense expected to be recorded 2026	68,000,000	68,000,000
Amortization expense expected to be recorded 2027	55,000,000	55,000,000
Loss on Disposal of a Business [Member]
Goodwill and Intangible Assets [Line Items]
Goodwill impairment		20,000,000
Restructuring charges	$ 49,000,000
Healthcare Distribution [Member]
Goodwill and Intangible Assets [Line Items]
Goodwill impairment		20,000,000
Restructuring charges		124,000,000	$ 6,000,000	$ 31,000,000
Healthcare Distribution [Member] \| Loss on Disposal of a Business [Member]
Goodwill and Intangible Assets [Line Items]
Restructuring charges		49,000,000
Healthcare Distribution [Member] \| Businesses Within [Member]
Goodwill and Intangible Assets [Line Items]
Impairment charge on intangible assets		49,000,000
Healthcare Distribution [Member] \| Businesses Within [Member] \| Loss on Disposal of a Business [Member]
Goodwill and Intangible Assets [Line Items]
Impairment charge on intangible assets		$ 15,000,000
Trademarks and Trade Names [Member] \| Weighted Average [Member]
Goodwill and Intangible Assets [Line Items]
Average useful life (in years)		8 years 4 months 24 days
Customer Relationships and Lists [Member] \| Weighted Average [Member]
Goodwill and Intangible Assets [Line Items]
Average useful life (in years)		10 years
Product Development [Member] \| Weighted Average [Member]
Goodwill and Intangible Assets [Line Items]
Average useful life (in years)		8 years 7 months 6 days
Noncompete Agreements [Member] \| Weighted Average [Member]
Goodwill and Intangible Assets [Line Items]
Average useful life (in years)		5 years 3 months 18 days

Goodwill and Other Intangibles, Net (Changes in the Carrying Amount of Goodwill) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021
Goodwill [Roll Forward]
Beginning balance	$ 2,854,000,000	$ 2,504,000,000
Adjustments to goodwill: Acquisitions	85,000,000	383,000,000
Adjustments to goodwill: Impairment	(20,000,000)	0
Adjustments to goodwill: Foreign currency translation	(26,000,000)	(33,000,000)
Ending balance	2,893,000,000	2,854,000,000
Health Care Distribution [Member]
Goodwill [Roll Forward]
Beginning balance	1,831,000,000	1,501,000,000
Adjustments to goodwill: Acquisitions	86,000,000	359,000,000
Adjustments to goodwill: Impairment	(20,000,000)
Adjustments to goodwill: Foreign currency translation	(22,000,000)	(29,000,000)
Ending balance	1,875,000,000	1,831,000,000
Technology and Value-Added Services [Member]
Goodwill [Roll Forward]
Beginning balance	1,023,000,000	1,003,000,000
Adjustments to goodwill: Acquisitions	(1,000,000)	24,000,000
Adjustments to goodwill: Impairment	0
Adjustments to goodwill: Foreign currency translation	(4,000,000)	(4,000,000)
Ending balance	$ 1,018,000,000	$ 1,023,000,000

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Goodwill and Other Intangibles, Net (Other Intangible Assets - Finite-Lived) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 1,097	$ 1,149
Accumulated amortization	(510)	(481)
Net	587	668
Customer Relationships and Lists [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	826	853
Accumulated amortization	(387)	(353)
Net	439	500
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	125	129
Accumulated amortization	(51)	(44)
Net	74	85
Product Development [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	90	114
Accumulated amortization	(56)	(70)
Net	34	44
Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	25	25
Accumulated amortization	(6)	(6)
Net	19	19
Other intangibles assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Cost	31	28
Accumulated amortization	(10)	(8)
Net	$ 21	$ 20

Investments and Other (Details) - USD ($) $ in Millions	12 Months Ended
Investments and Other (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investments in unconsolidated affiliates	$ 161	$ 168
Non-current deferred foreign, state and local income taxes	88	35
Notes receivable	28	36
Capitalized costs for internally generated software for resale	79	65
Security deposits	3	2
Acquisition related indemnification	59	66
Non-current pension assets	8	0
Other long-term assets	46	52
Total	472	424
Amortization of other long-term assets	$ 18	$ 15	$ 16
Financing Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Latest maturity date of varying installments of long-term notes receivable	May 11, 2028
Financing Receivable [Member] \| Minimum [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long-term notes receivable interest rate (as a percent)	3.00%
Financing Receivable [Member] \| Maximum [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Long-term notes receivable interest rate (as a percent)	7.50%

Fair Value Measurements (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 576	$ 613	$ 328	$ 287
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt	1,149	873
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps		1
Total assets		10
Liabilities [Abstract]
Total return swaps	3
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Designated As Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	23	8
Liabilities [Abstract]
Derivative contracts - liabilities	1	1
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Not Designated as Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	4	1
Liabilities [Abstract]
Derivative contracts - liabilities	3	2
Fair value, measurements, recurring [Member]
Assets [Abstract]
Total assets	27
Liabilities [Abstract]
Total liabilities	7	3
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	576	613
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps		0
Total assets		0
Liabilities [Abstract]
Total return swaps	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Designated As Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Not Designated as Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Total assets	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps		1
Total assets		10
Liabilities [Abstract]
Total return swaps	3
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Designated As Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	23	8
Liabilities [Abstract]
Derivative contracts - liabilities	1	1
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Not Designated as Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	4	1
Liabilities [Abstract]
Derivative contracts - liabilities	3	2
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Total assets	27
Liabilities [Abstract]
Total liabilities	7	3
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total return swaps		0
Total assets		0
Liabilities [Abstract]
Total return swaps	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Designated As Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Not Designated as Hedging Instrument [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Total assets	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 576	$ 613

Concentrations of Risk (Details)	12 Months Ended
Concentrations of Risk (Details)	Dec. 31, 2022
Top customer concentration risk [Member] \| Sales revenue, net [Member] \| Any single customer [Member] \| Maximum [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	2.00%
Supplier concentration risk [Member] \| Purchases [Member] \| Top ten health care distribution suppliers [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	28.00%
Supplier concentration risk [Member] \| Purchases [Member] \| Single largest supplier [Member]
Concentration Risk [Line Items]
Concentration risk percentage (as a percent)	4.00%

Derivatives and Hedging Activities (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 25, 2021 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 USD ($)	Mar. 20, 2020 USD ($)
Other Comprehensive Income [Member] \| Foreign Exchange Forward [Member]
Derivative [Line Items]
Gain (loss) on derivative	$ (9)	$ (11)
Total Return Swap [Member] \| SERP and DCP [Member]
Derivative [Line Items]
Derivative, Notional Amount				$ 78	$ 43
Derivative, Inception Date	Mar. 20, 2020
Gain (loss) on derivative	$ (17)	$ 12
Total Return Swap [Member] \| Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member] \| SERP and DCP [Member]
Derivative [Line Items]
Derivative, Variable Interest Rate			4.58%	4.58%
Derivative, Basis Spread on Variable Rate			4.03%	4.03%
Derivative Fixed Interest Rate			0.55%	0.55%
Net Investment Hedging [Member] \| Forward Contracts [Member]
Derivative [Line Items]
Derivative, Notional Amount \| €			€ 200
Derivative, Maturity Dates	Nov. 16, 2023

Debt (Revolving Credit Agreement and Other Short-Term Bank Credit Lines - Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021
Line of Credit Facility [Line Items]
Bank credit lines	$ 103,000,000	$ 51,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Initiation date	Aug. 20, 2021
Revolving credit facility borrowing capacity	$ 1,000,000,000.0
Revolving credit facility expiration date	Aug. 20, 2026
Line of credit facility, amount outstanding	$ 0	0
Bank credit lines	0	0
Outstanding letters of credit provided to third parties	9,000,000	9,000,000
Revolving Credit Facility April 2022 [Member]
Line of Credit Facility [Line Items]
Revolving credit facility borrowing capacity	750,000,000
Various Bank Credit Lines [Member]
Line of Credit Facility [Line Items]
Revolving credit facility borrowing capacity	402,000,000
Bank credit lines	$ 103,000,000	$ 51,000,000
Weighted average interest rate on borrowings under credit lines at period end (as a percent)	10.11%	10.44%

Debt (Private Placement Facilities - Narrative) (Details) - Private Placement Facilities [Member] $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 25, 2021 USD ($)
Debt Instrument [Line Items]
Debt instrument maximum borrowing capacity	$ 1.5	$ 1,000.0
Debt instrument, maturity date	Oct. 20, 2026	Jun. 23, 2023
Average term of issuances under private placement facilities	12 years
Increase in maximum maintenance leverage ratio	1.00%
Net leverage ratio	0.030
Date of borrowing	Oct. 20, 2021
Weighted average interest rate on borrowings under credit lines at period end (as a percent)	2.99%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years
Net leverage ratio	0.0325

Debt (U.S. Trade Accounts Receivable Securitization - Narrative) (Details) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2022 USD ($) number	Sep. 24, 2022	Dec. 31, 2022 USD ($) number	Dec. 25, 2021 USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 1,046		$ 1,046	$ 822
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Pricing commitment period			3 years
Debt instrument, maturity date	Dec. 15, 2025	Oct. 18, 2024
Debt instrument maximum borrowing capacity	$ 450		$ 450
Number of banks as agents for debt instrument \| number	2		2
Long-term debt	$ 330		$ 330	$ 105
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)	0.30%		0.30%
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)	0.35%		0.35%
U.S. trade accounts receivable securitization [Member] \| Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, variable rate basis at period end	4.58%		4.58%	0.19%
Debt instrument, basis spread on variable rate			0.75%	0.75%
Debt instrument, interest rate at period end	5.33%		5.33%	0.94%

Debt (Bank Credit Lines) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Line of Credit Facility [Line Items]
Bank credit lines	$ 103	$ 51
Revolving credit facility [Member]
Line of Credit Facility [Line Items]
Bank credit lines	0	0
Other short-term bank credit lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines	103	51
Committed Loan Associated with Animal Health Spin-off [Member]
Line of Credit Facility [Line Items]
Bank credit lines	$ 103	$ 51

Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Debt Instrument [Line Items]
Long-term debt	$ 1,046	$ 822
Finance lease obligations	10	7
Less current maturities	(6)	(11)
Total long-term debt	1,040	811
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Long-term debt	699	706
U.S. trade accounts receivable securitization [Member]
Debt Instrument [Line Items]
Long-term debt	330	105
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member]
Debt Instrument [Line Items]
Long-term debt	$ 7	$ 4
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	0.00%	2.62%
Various collateralized and uncollateralized long-term loans payable with interest, in varying installments [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	3.50%	4.27%

Debt (Private Placement Facilities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1)
Total Long-term debt	$ 1,046	$ 822
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Date of borrowing	Oct. 20, 2021
Less: Deferred debt issuance costs	$ (1)
Total Long-term debt	$ 699	$ 706
Due date	Oct. 20, 2026	Jun. 23, 2023
Private Placement Facilities [Member] \| Private placement facilities maturing in January 2024 [Member]
Debt Instrument [Line Items]
Date of borrowing	Jan. 20, 2012
Amount of borrowing outstanding	$ 50
Borrowing Rate	3.45%
Due date	Jan. 20, 2024
Private Placement Facilities [Member] \| Private placement facilities maturing in December 2024 [Member]
Debt Instrument [Line Items]
Date of borrowing	Dec. 24, 2012
Amount of borrowing outstanding	$ 50
Borrowing Rate	3.00%
Due date	Dec. 24, 2024
Private Placement Facilities [Member] \| Private Placement facilities maturing in June 2027 [Member]
Debt Instrument [Line Items]
Date of borrowing	Jun. 16, 2017
Amount of borrowing outstanding	$ 100
Borrowing Rate	3.42%
Due date	Jun. 16, 2027
Private Placement Facilities [Member] \| Private Placement Facilities maturing in September 2029 [Member]
Debt Instrument [Line Items]
Date of borrowing	Sep. 15, 2017
Amount of borrowing outstanding	$ 100
Borrowing Rate	3.52%
Due date	Sep. 15, 2029
Private Placement Facilities [Member] \| Private Placement facilities maturing in January 2028 [Member]
Debt Instrument [Line Items]
Date of borrowing	Jan. 02, 2018
Amount of borrowing outstanding	$ 100
Borrowing Rate	3.32%
Due date	Jan. 02, 2028
Private Placement Facilities [Member] \| Private placement facilities maturing in September 2030 [Member]
Debt Instrument [Line Items]
Date of borrowing	Sep. 02, 2020
Amount of borrowing outstanding	$ 100
Borrowing Rate	2.35%
Due date	Sep. 02, 2030
Private Placement Facilities [Member] \| Private placement facilities maturing in June 2031 [Member]
Debt Instrument [Line Items]
Date of borrowing	Jun. 02, 2021
Amount of borrowing outstanding	$ 100
Borrowing Rate	2.48%
Due date	Jun. 02, 2031
Private Placement Facilities [Member] \| Private placement facilities maturing in June 2033 [Member]
Debt Instrument [Line Items]
Date of borrowing	Jun. 02, 2021
Amount of borrowing outstanding	$ 100
Borrowing Rate	2.58%
Due date	Jun. 02, 2033

Debt (Schedule of Long-Term Debt Maturities) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Maturities of Long-term Debt [Abstract]
2023	$ 6
2024	109
2025	331
2026	0
2027	100
Thereafter	$ 500

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020	Dec. 28, 2019
Income Tax Examination [Line Items]
Effective tax rate (as a percent)	23.50%	23.80%	19.10%
Allowable business interest deduction rate after modification to Section 163(j)	50.00%
Allowable business interest deduction rate before modification to Section 163(j)	30.00%
Unrecognized tax benefits	$ 82	$ 71	$ 70	$ 91
Tax interest expense (credit)	0	0	$ (3)
Accrued Taxes [Member]
Income Tax Examination [Line Items]
Tax Cuts And Jobs Act Of 2017 Transition Tax For Accumulated Foreign Earnings Liability Current	19	14
Other Liabilities [Member]
Income Tax Examination [Line Items]
Tax Cuts And Jobs Act Of 2017 Transition Tax For Accumulated Foreign Earnings Liability Current	23	42
Unrecognized tax benefits	94	84
Unrecognized tax benefits that would affect the effective tax rate if recognized	80	69
Total interest	12	$ 12
Domestic Tax Authority [Member]
Income Tax Examination [Line Items]
Operating loss carryforwards	30
Net operating loss carryforwards not subject to expiration	21
Foreign Tax Authority [Member]
Income Tax Examination [Line Items]
Operating loss carryforwards	220
Net operating loss carryforwards not subject to expiration	218
State and Local Jurisdiction [Member]
Income Tax Examination [Line Items]
Operating loss carryforwards	31
Net operating loss carryforwards not subject to expiration	$ 4

Income Taxes (Income Before Taxes, Equity in Earnings of Affiliates and Loss on Sale of Equity Investment) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Income before equity method investments, income taxes and loss on sale of equity investment [Abstract]
Domestic	$ 506	$ 593	$ 431
Foreign	215	238	69
Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests	$ 721	$ 831	$ 500

Income Taxes (Provision for Income Taxes Attributable to Continuing Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Current income tax expense:
U.S. Federal	$ 150	$ 129	$ 83
State and local	49	37	24
Foreign	44	43	41
Total current	243	209	148
Deferred income tax expense (benefit):
U.S. Federal	(48)	(12)	(18)
State and local	(13)	(3)	(5)
Foreign	(12)	4	(30)
Total deferred	(73)	(11)	(53)
Total income tax provision	$ 170	$ 198	$ 95

Income Taxes (Tax Effects of Temporary Differences to Deferred Income Tax Asset (Liability)) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Deferred income tax asset:
Net operating losses and other carryforwards	$ 64	$ 55
Inventory, premium coupon redemptions and accounts receivable valuation allowances	57	46
Stock-based compensation	11	13
Uniform capitalization adjustment to inventories	11	10
Operating lease liability	77	79
Other asset	48	41
Total deferred income tax asset	268	244
Valuation allowance for non-current deferred tax assets	(36)	(36)
Net deferred income tax asset	232	208
Deferred income tax liability
Intangibles amortization	(112)	(134)
Operating lease right-of-use asset	(61)	(74)
Property and equipment	(7)	(7)
Total deferred tax liability	(180)	(215)
Net deferred income tax asset (liability)	$ 52	$ (7)

Income Taxes (Operating Loss Carryforwards) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Foreign tax authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards not subject to expiration	$ 218
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards not subject to expiration	4
Federal tax authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards not subject to expiration	$ 21

Income Taxes (Reconciliation of Income Tax Provision at Federal Statutory Rate to Total Income Tax Provision) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax provision at federal statutory rate	$ 151	$ 175	$ 105
State income tax provision, net of federal income tax effect	20	21	13
Foreign income tax provision	4	6	0
Pass through noncontrolling interest	(4)	(4)	(3)
Valuation allowance	(2)	(6)	1
Unrecognized tax benefits and audit settlements	11	7	(18)
Interest expense related to loans	(12)	(11)	(11)
Tax benefit related to legal entity reorganization outside the U.S.	0	0	(6)
Other	2	10	14
Total income tax provision	$ 170	$ 198	$ 95

Income Taxes (Reconciliation of Unrecognized Tax Benefits Excluding the Effect of Deferred Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of period	$ 71	$ 70	$ 91
Additions based on current year tax positions	14	3	5
Additions based on prior year tax positions	8	11	8
Reductions based on prior year tax positions	0	(1)	(1)
Reductions resulting from settlements with taxing authorities	(1)	(9)	(19)
Reductions resulting from lapse in statutes of limitations	(10)	(3)	(14)
Balance, end of period	$ 82	$ 71	$ 70

Plans of Restructuring and Integration Costs (Narrative) (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($) number	Dec. 31, 2022 USD ($) number
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 128	$ 128
Midway Dental Supply [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	9
Integration costs	$ 3
Building Vacated [Member]
Restructuring Cost and Reserve [Line Items]
Number of buildings vacated \| number	1	1
Accelerated amortization of right of use lease asset expense	$ 34
Loss on Disposal of a Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 49

Plans of Restructuring and Integration Costs (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 128	$ 128
Total		131	$ 8	$ 32
Severance And Employee Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total		29	8	26
Impairment and Accelerated Depreciation and Amortiztion of Right-of-Use Lease Assets and Other Long Long-Lived Assets [Member]
Restructuring Cost and Reserve [Line Items]
Total		47
Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Total				4
Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total		3		2
Loss on Disposal of a Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 49
Total		49
Integration Employee Related and Other Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total		3
Healthcare Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		124	6	31
Integration Costs		3
Healthcare Distribution [Member] \| Severance And Employee Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		25	6	25
Healthcare Distribution [Member] \| Impairment and Accelerated Depreciation and Amortiztion of Right-of-Use Lease Assets and Other Long Long-Lived Assets [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		47
Healthcare Distribution [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs				4
Healthcare Distribution [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		3		2
Healthcare Distribution [Member] \| Loss on Disposal of a Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		49
Healthcare Distribution [Member] \| Integration Employee Related and Other Costs [Member]
Restructuring Cost and Reserve [Line Items]
Integration Costs		3
Technology And Value Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		4	2	1
Technology And Value Added Services [Member] \| Severance And Employee Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		$ 4	$ 2	$ 1

Plans of Restructuring and Integration Costs (Schedule of Restructuring Reserve by Segment) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Restructuring Reserve [Roll Forward]
Balance, beginning		$ 4
Restructuring charges	$ 128	128
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets		(47)
Non-cash impairment on disposal of a business		(46)
Cash payments and other adjustments		(15)
Balance, ending	24	24	$ 4
Health Care Distribution [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		3
Restructuring charges		124	6	$ 31
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets		(47)
Non-cash impairment on disposal of a business		(46)
Cash payments and other adjustments		(13)
Balance, ending	21	21	3
Technology and Value-Added Services [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		1
Restructuring charges		4
Cash payments and other adjustments		(2)
Balance, ending	3	3	$ 1
Loss on Disposal of a Business [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 49
Loss on Disposal of a Business [Member] \| Health Care Distribution [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges		$ 49

Commitments and Contingencies - Unrecorded Unconditional Purchase Obligation (Details) $ in Millions	Dec. 31, 2022 USD ($)
Unrecorded Unconditional Purchase Obligation [Abstract]
2022	$ 5
2023	4
2024	4
2025	4
2026	4
Thereafter	0
Total minimum inventory purchase commitment payments	$ 21

Commitments and Contingencies - Other Commitments (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Employment, consulting and non-compete agreements [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
2022	$ 23,000,000
2023	7,000,000
2024	5,000,000
2025	0
2026	0
Thereafter	0
Life-time consulting agreement [Member]
Other Commitment, Fiscal Year Maturity [Abstract]
Current compensation paid under lifetime consulting agreement	400,000
Amount of increase effective every fifth year on lifetime consulting agreement	$ 25,000

Commitments and Contingencies - Litigation (Details)	1 Months Ended	12 Months Ended
Commitments and Contingencies - Litigation (Details)	Dec. 31, 2022 USD ($) number claims	Dec. 31, 2022 USD ($) number	Dec. 25, 2021 USD ($)	Dec. 26, 2020 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Net sales		$ 12,647,000,000	$ 12,401,000,000	$ 10,119,000,000
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of pending claims \| number	150	150
DCH Health Care Authority Et Al [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plantiffs set for jury trial		8
Number of plantiffs		38
Other Hospitals Located Throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plantiffs		38
Cases In Utah [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plantiffs	19
Number of cases settled \| claims	7
Litigation settlements	$ 60,000
Number of cases dismissed	7
Actions consolidated in the MultiDistrict Litigation [Member] \| Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage	0.20%
Actions consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Net sales		$ 12,600,000,000

Stock Based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax share-based compensation expense	$ 54.0	$ 78.0	$ 9.0
After-tax share-based compensation expense	41.0	$ 60.0	$ 7.0
Total unrecognized compensation cost related to non-vested awards	$ 75.0
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)	2 years 1 month 6 days
Liability related to grant date fair value of stock-based compensation to be settled in cash	$ 0.4
Expected life of options (years)	6 years
Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value of stock-based awards granted before forfeitures (in dollars per share)	$ 85.51	$ 62.72	$ 60.23
Intrinsic value (in dollars per share)	$ 78.74	$ 73.99	$ 61.49
Time-Based Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	4 years
Weighted-average grant date fair value of stock-based awards granted before forfeitures (in dollars per share)	$ 85.49
Intrinsic value (in dollars per share)	$ 79.87
Performance-Based Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years
Weighted-average grant date fair value of stock-based awards granted before forfeitures (in dollars per share)	$ 82.35
Intrinsic value (in dollars per share)	$ 79.87
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years
Percentage of stock options vest per year	33.33%
Expiration period (in years)	10 years
2020 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	70,942,657
Shares available to be granted (in shares)	8,034,696
2020 Stock Incentive Plan [Member] \| Special Pandemic Recognition Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	2 years
Stock based compensation percentage of options vest per year first anniversary	50.00%
Stock based compensation percentage of options vest per year second anniversary	50.00%
Cumulative percentage payout based on actual performance and one-time special award	75.00%
2020 Stock Incentive Plan [Member] \| Performance-Based Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage payout based on actual performance	20.00%
2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be granted (in shares)	1,892,657
Shares available to be granted (in shares)	192,400
2015 Non-Employee Director Stock Incentive Plan [Member] \| Time-Based Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	12 months
2018 Long-Term Incentive Program [Member] \| Performance-Based Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)	3 years

Stock Based Compensation (Valuation Model) (Details)	12 Months Ended
Stock Based Compensation (Valuation Model) (Details)	Dec. 31, 2022
Stock Based Compensation [Abstract]
Expected dividend yield	0.00%
Expected stock price volatility	27.80%
Risk-free interest rate	3.62%
Expected life of options (years)	6 years

Stock Based Compensation (Summary of Stock Option Activity Under the Plans) (Details) - Stock Options [Member] $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares) \| shares	767,717
Granted (in shares) \| shares	420,075
Exercised (in shares) \| shares	(36,150)
Forfeited (in shares) \| shares	(34,068)
Outstanding at end of period (in shares) \| shares	1,117,574
Ending balance, options exercisable (in shares) \| shares	220,688
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 63.24
Granted (in dollars per share) \| $ / shares	85.81
Exercised (in dollars per share) \| $ / shares	62.92
Forfeited (in dollars per share) \| $ / shares	74.84
Outstanding at end of period (in dollars per share) \| $ / shares	71.38
Ending balance, options exercisable (in dollars per share) \| $ / shares	$ 63.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	8 years 6 months
Outstanding at end of period, Aggregate Intrinsic Value \| $	$ 12

Stock-Based Compensation (Intrinsic Values) (Details) - Employee And Directors Stock Options [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	885,428
Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 73.50
Weighted Average Remaining Contractual Life (in years)	8 years 8 months 12 days
Aggregate Intrinsic Value \| $	$ 8,000

Stock Based Compensation (Status of Non-Vested Restricted Shares/Units) (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Time-Based Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,945,862
Granted (in shares) \| shares	471,840
Vested (in shares) \| shares	(566,887)
Forfeited (in shares) \| shares	(94,771)
Ending balance outstanding (in shares) \| shares	1,756,044
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 58.79
Granted (in dollars per share)	85.49
Vested (in dollars per share)	55.46
Forfeited (in dollars per share)	67.87
Ending balance outstanding (in dollars per share)	66.59
Intrinsic value (in dollars per share)	$ 79.87
Performance-Based Restricted Stock/Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	674,753
Granted (in shares) \| shares	267,865
Vested (in shares) \| shares	(396,220)
Forfeited (in shares) \| shares	(25,482)
Ending balance outstanding (in shares) \| shares	520,916
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 59.63
Granted (in dollars per share)	82.35
Vested (in dollars per share)	59.21
Forfeited (in dollars per share)	67.65
Ending balance outstanding (in dollars per share)	60.23
Intrinsic value (in dollars per share)	$ 79.87

Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Management [Member] \| Deferred compensation bonus and commission plan [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation plan fair market value amount charged (credited) to operations	$ (11)	$ 8	$ 8
Qualified 401K plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Maximum matching contributions as a percentage of participants' contributions (as a percent)	100.00%
Maximum participants' contributions as a percentage of their base compensation (as a percent)	7.00%
Allowable maximum percentage of contributions allocated to Henry Schein Stock Fund (as a percent)	20.00%
Amounts charged (credited) to operations	$ 45	38	21
Qualified 401K plan [Member] \| Selling General And Administrative Expenses [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	37
Qualified 401K plan [Member] \| Cost of Goods Sold [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	8
Supplemental executive retirement plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Amounts charged (credited) to operations	$ (1)	$ 2	$ 3

Employee Benefit Plans (Obligation and Funded Status) (Details) - Pension Plans Defined Benefit [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Defined Benefit Plan Disclosure [Line Items]
Balance	$ 128	$ 130
Defined Benefit Plan Service Cost	3	4	$ 3
Defined Benefit Plan Interest Cost	1	0
Defined Benefit Plan, Benefit Obligation, Past Service (Cost) and Credit	0	5
Defined Benefit Plan Actuarial Gain Loss	(19)	(5)
Defined Benefit Plan Benefit Obligation Benefits Paid	(1)	0
Defined Benefit Plan Benefit Obligation Contributions By Plan Participant	1	1
Defined Benefit Plan Settlements Benefit Obligation	(1)	(2)
Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation	(4)	(5)
Balance	108	128	130
Defined Benefit Plan Change In Fair Value Of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of period	75	65
Actual return on plan assets	(3)	5
Employer contributions	2	2
Plan participant contributions	1	1
Expected return on plan assets	1	4
Benefit received	0	2
Settlements	(1)	(3)
Effect of foreign currency translation	(2)	(1)
Fair value of plan assets at end of period	73	75	$ 65
Unfunded Plan [Member]
Defined Benefit Plan Change In Fair Value Of Plan Assets [Roll Forward]
Defined Benefit Plan Funded Status Of Plan	35	53
Funded Plan [Member]
Defined Benefit Plan Change In Fair Value Of Plan Assets [Roll Forward]
Defined Benefit Plan Funded Status Of Plan	$ 6	$ 6

Employee Benefit Plans (Balance Sheet) (Details) - Pension Plans Defined Benefit [Member] - USD ($) $ in Millions	Dec. 31, 2022	Dec. 25, 2021
Defined Benefit Plan Disclosure [Line Items]
Non-current assets	$ 25	$ 22
Current liabilities	(1)	(1)
Non-current liabilities	(59)	(74)
Accumulated other comprehensive loss, pre-tax	$ 4	$ 21

Employee Benefit Plans (Net Periodic Pension Cost) (Details) - Pension Plans Defined Benefit [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Service Cost	$ 3	$ 4	$ 3
Defined Benefit Plan Interest Cost	1	0
Defined Benefit Plan Expected Return On Plan Assets	(1)	(1)
Defined Benefit Plan Amortization Of Prior Service Cost Credit	1	1	1
Total	$ 4	$ 4	$ 4

Employee Benefit Plans (Assumptions) (Details) - Pension Plans Defined Benefit [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate	1.67%	0.87%
Defined Benefit Plan Weighted Average Assumptions Used In Calculating Net Periodic Benefit Cost [Abstract]
Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate	1.25%	0.56%	0.51%
Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets	0.81%	0.71%	0.87%
Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase	1.68%	1.95%	1.97%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Pension Rate	0.61%	0.72%	0.67%

Employee Benefit Plans (Estimated Payments) (Details) - Pension Plans Defined Benefit [Member] $ in Millions	Dec. 31, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months	$ 6
Defined Benefit Plan Expected Future Benefit Payments Year Two	6
Defined Benefit Plan Expected Future Benefit Payments Year Three	5
Defined Benefit Plan Expected Future Benefit Payments Year Four	5
Defined Benefit Plan Expected Future Benefit Payments Year Five	7
Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter	38
Total	$ 67

Redeemable Noncontrolling Interests (Change in Fair Value of Redeemable Noncontrolling Interests) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period	$ 613	$ 328	$ 287
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries	(31)	(60)	(17)
Increase in redeemable noncontrolling interests due to business acquisitions	4	189	28
Net income attributable to redeemable noncontrolling interests	21	23	14
Dividends declared	(21)	(21)	(13)
Effect of foreign currency translation loss attributable to redeemable noncontrolling interests	(6)	(6)	(4)
Change in fair value of redeemable securities	(4)	160	33
Balance, end of period	$ 576	$ 613	$ 328

- Definition

Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

Comprehensive Income (Accumulated Other Comprehensive Income and Comprehensive Income Components) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (37)	$ (31)	$ (25)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(1)	0	0
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(236)	(155)	(77)
Unrealized gain (loss) from foreign currency hedging activities	5	(2)	(11)
Pension adjustment loss	(2)	(14)	(20)
Accumulated other comprehensive loss	(233)	(171)	(108)
Total Accumulated other comprehensive loss	(271)	(202)	(133)
Components of comprehensive income [Abstract]
Net Income	566	660	420
Foreign currency translation gain (loss)	(88)	(84)	63
Tax effect	0	0	0
Foreign currency translation gain (loss)	(88)	(84)	63
Unrealized gain (loss) from foreign currency hedging activities	10	12	(10)
Tax effect	(3)	(3)	3
Unrealized gain (loss) from foreign currency hedging activities	7	9	(7)
Tax effect	0	0	0
Pension adjustment gain	16	8	0
Tax effect	(4)	(2)	0
Pension adjustment gain	12	6	0
Comprehensive income	$ 497	$ 591	$ 476

Comprehensive Income (Total Comprehensive Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 476	$ 568	$ 463
Comprehensive income attributable to noncontrolling interests	6	6	3
Comprehensive income attributable to Redeemable noncontrolling interests	15	17	10
Comprehensive income	$ 497	$ 591	$ 476

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

Discontinued Operations (Narrative) (Details) - USD ($) $ in Millions		12 Months Ended
	Feb. 07, 2019	Dec. 31, 2022	Dec. 26, 2020
Covetrus, Inc. [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Period services provided according to transition service agreement		24 months
Henry Schein Animal Health Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transaction costs related to Animal Health spin-off			$ 0
Henry Schein Animal Health Business [Member] \| Covetrus, Inc. [Member] \| Henry Schein stockholders and the Share Sale Investors [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling interest, ownership percentage	37.00%
Henry Schein Animal Health Business [Member] \| Covetrus, Inc. [Member] \| Vets First Corp [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution received related to Animal Health Spin-off	$ 1,120
Proceeds related to Animal Health Share Sale	$ 361
Noncontrolling interest, ownership percentage	63.00%

Discontinued Operations (Summarized Financial Information for Discontinued Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Summarized financial information for our discontinued operations
Costs of goods sold	$ 8,816	$ 8,727	$ 7,303
Selling, general and administrative	2,771	2,634	2,086
Income from discontinued operations	0	0	1
Net income attributable to Henry Schein, Inc.	$ 538	$ 631	404
Henry Schein Animal Health Business [Member]
Summarized financial information for our discontinued operations
Selling, general and administrative			2
Operating income (loss)			(2)
Income tax expense (benefit)			(3)
Income from discontinued operations			1
Net income attributable to Henry Schein, Inc.			$ 1

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

+ Details

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Earnings Per Share (Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Weighted-average common shares outstanding:
Basic (in shares)	136,064,221	140,090,889	142,504,193
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units (in shares)	1,691,449	1,681,892	899,489
Diluted (in shares)	137,755,670	141,772,781	143,403,682

Earnings Per Share (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	362,182	612,917	2,398
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	342,716	611,869	0
Restricted Stock/Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	19,466	1,048	2,398

Supplemental Cash Flow Information (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Supplemental Cash Flow Elements [Abstract]
Unrealized gain (loss) from foreign currency hedging activities	$ 10	$ 12	$ (10)

Supplemental Cash Flow Information (Cash Paid for Interest and Income Taxes) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Supplemental Cash Flow Elements [Abstract]
Interest	$ 47	$ 29	$ 43
Income taxes	$ 265	$ 242	$ 207

Related Party Transactions (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 25, 2021	Dec. 26, 2020
Related Party Transaction [Line Items]
Due to related party	$ 6	$ 7
Due from related party	$ 36	44
Covetrus, Inc. [Member]
Related Party Transaction [Line Items]
Period services provided according to transition service agreement	24 months
Costs from transactions with related party			$ 13
Revenue from related party			75
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Due from (to) related party	$ (8)	9
Internet Brands Inc [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Costs from transactions with related party	$ 31	31	31
Internet Brands Inc [Member] \| Scenario, Plan [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Royalty agreement term (in years)	10 years
Amount of transaction	$ 31
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Revenue from related party	46	48	38
Purchases from related party	$ 9	$ 15	$ 12